To help find answers, researchers at the Institute for Neuroscience, Neurotechnology, and Society (INNS) are using math, data, and AI to unlock the secrets of thought. Together they are helping turn the brain’s raw electrical “noise” into real insights about how people think, move, and perceive the world.

Fair warning: Prepare your neurons for the complexity of this brain research ahead.

Building AI Like a Brain

What if artificial neurons in AI programs were arranged as they are in the brain?

AI programs would then help us understand why the brain is organized the way it is. This neuro-AI synthesis would also work faster, use less energy, and be easier to interpret. Creating such systems is the goal of Apurva Ratan Murty, an assistant professor of Psychology who is creating topographic AI models like the one above of three domains — vision, audition, and language inspired by the brain. In the near future, he predicts doctors might be able to use these patterns to predict the effects of brain lesions and other disorders. “We’re not there yet,” he says. “But our work brings us significantly closer to that future than ever before.”

Computing Thought and Movement

How cats walk keeps Chethan Pandarinath on his toes. This biomedical engineer uses sensors to analyze how two sets of feline leg muscles — flexors and extensors — are controlled by the spinal cord. Understanding how that happens could help patients partially paralyzed from spinal cord injuries, strokes, or progressive neuro-degenerative diseases get back on their feet again. “My lab is using AI tools that allow us to turn complex spinal cord activity data into something we can interpret. It tells us there’s a simple underlying structure behind the complex activity patterns,” says the associate professor.

Revealing the Brain’s Spike Patterns

“The brain is like a symphony conductor,” says Simon Sponberg. “Individual instruments have some independent control, but most of the music comes from the brain’s precise coordination of notes among the different players in the body.” This physics professor studies the fantastically fast-beating wings of the hummingbird-sized hawk moth (Manduca sexta). Its agile flight movement comes as a result of spikes in electrical activity in 10 muscles. Sponberg found something that surprised him — the brain focuses less on creating the number of spikes than in orchestrating their precise patterns over time. To Sponberg, every millisecond matters. “We are just beginning to understand how the nervous system first acquires precisely timed spiking patterns during development,” he says.

Predicting Decisions Through Statistics

Put a mouse in a maze with food far away, and it will learn to find it. But life for mice — and people — isn’t so simple. Sometimes they want to explore, only want water, or just want to go home. What’s more, animals make decisions based on their history, not just on how they feel at the moment. To dig deeper into the decision-making process, Anqi Wu, an assistant professor in the School of Computational Science and Engineering, is giving mice more options. By using a new computational framework called SWIRL (Switching Inverse Reinforcement Learning), her findings have outperformed models that fail to take historical behavior into account. “We’re seeking to understand not only animal behavior but also human behavior to gain insight into the human decision-making process over a long period of time,” she says.

Modeling the Mind’s Wiring With Math

Connectivity shapes cognition in the cerebral cortex, a layered structure in the brain. The visual cortex, in particular, processes visual data from the retina relayed through the Lateral Geniculate Nucleus (LGN) in the thalamus, and directs it to the correct cognitive domain in the brain. How it does this is the mystery that computational neuroscientist Hannah Choi wants to solve. “The big question I’m interested in is how network connectivity patterns in the architecture of the LGN are related to computations,” says this assistant math professor. To find answers, she shows mice repeated image patterns such as flower-cat-dog-house and then disrupts the pattern. The goal? To grasp how the thalamus’s nonlinear dynamical system works. If scientists and doctors better understand how brain regions are wired together, such knowledge could lead to better disease treatment.

This story was originally published through the Georgia Tech Alumni Magazine. Read the original publication here.

Prausnitz, a Regents’ Professor, Regents’ Entrepreneur, and J. Erskine Love Jr. Chair in the School of Chemical and Biomolecular Engineering, is this year’s recipient of the Class of 1934 Distinguished Professor Award. 

“While I may be the focal point, it’s not a recognition of me as an individual. It’s a recognition of everything the team has done,” Prausnitz said. “I know how to do some things, but there are many things I don’t know how to do. That’s why working with others matters. You bring people together, fill in the gaps, and solve the whole problem.” 

The “some things” Prausnitz knows how to do have led to revolutionary medical innovation over a 30-year career at Georgia Tech, where he has led transformative work in microneedle drug delivery, launching 10 companies in the process. 

During that time, Prausnitz published hundreds of peer-reviewed papers, was granted dozens of patents, and advanced his work from early laboratory studies into more than 20 human clinical trials. His research has produced multiple FDA‑approved or clinically tested technologies. 

Understanding Prausnitz’s success starts with his approach to engineering in practice. Science may begin with discovery, but engineering, as he describes it, focuses on taking something uncertain and making it work. 

“One of the things that really distinguishes engineering from science is the work of problem-solving to reach an answer,” he said. “You start with something diffuse and figure out how to put all the pieces together. That to me is a hallmark of engineering.” 

That way of thinking took shape early in his life. 

Read the full story.

It’s not glamorous. It’s not trendy. In fact, it’s downright grubby. But the work that a Georgia Tech researcher and his students are doing is improving campus sustainability, one pound of food waste at a time. 

The Academy recognizes leaders across fields of study who have addressed humanity’s greatest challenges while also gathering knowledge to advance learning and the public good. This year’s class of 252 honorees was elected in academia, the arts, industry, journalism, philanthropy, policy, research, and science.  

García is one of nine honorees in the “Engineering and Technology” division. His research — both in the George W. Woodruff School of Mechanical Engineering where he serves as Regents’ Professor and in the Parker H. Petit Institute for Bioengineering and Bioscience where he is the executive director — aligns with the Academy’s service-minded mission.  

“I am inspired to find engineering solutions to serious health conditions to help people,” he said. “As a kid, I developed a musculoskeletal condition that required biomaterial devices to treat. Although imperfect, this treatment allowed me to lead a normal life.” 

Moved by his personal experience, García’s research centers on cellular and tissue engineering, which integrate biological and engineering principles to restore organ function lost to injury or disease. By studying how cells interact with the materials around them, he and his team have engineered biomaterials for the controlled delivery of therapeutic proteins and cells that enhance tissue regeneration, which could speed the healing process for patients.  

His future work will integrate biomaterials with lab‑grown replicas of human organs, known as organoids, that can be used to identify new therapies for a variety of human diseases. These organoids, though smaller and simpler than true organs, can mimic key functions that may help García and his team to find better ways to repair damaged tissues. 

García has spent the past 27 years at Georgia Tech and carries on the legacy of another Academy member — the Petit Institute’s founding executive director Robert Nerem, who was inducted in 1998. García credits his success to the support of his loved ones and the Yellow Jacket community.  

“I am deeply honored and humbled,” he said. “This award is only possible by the unending love and support of family, friends and mentors, my phenomenal past and present trainees, fantastic collaborators, and awesome ecosystem at Georgia Tech.” 

The Academy was chartered in 1780 during the American Revolution by a group that included John Adams and John Hancock. It was established to recognize accomplished individuals and engage them in addressing the greatest challenges facing the young republic. 

Membership has broadened over the years to celebrate excellence in a variety of fields. Honorees have included poet Robert Frost, musician John Legend, and chef José Andrés, who was given this year’s Ivan Allen Jr. Prize for Social Courage.  

García and the rest of this year’s class, which includes actor Jodie Foster, will be inducted in October.  

Students, faculty, and researchers from Georgia Tech and Kennesaw State University gathered on April 8 for a joint workshop between Georgia Tech's NSF Sustainable Development of Smart Medical Devices (SUSMED) program and KSU's Mobility for Everyone (MOVE) Center. The full-day event explored how sustainable design, mobility science, and health technologies are converging to shape the next generation of medical devices.  

In December, The Conversation hosted a webinar on AI’s revolutionary role in drug discovery and development.

Science and technology editor Eric Smalley interviewed Jeffrey Skolnick, eminent scholar in computational systems biology at Georgia Institute of Technology, and Benjamin P. Brown, assistant professor of pharmacology at Vanderbilt University.

Skolnick has developed AI-based approaches to predict protein structure and function that may help with drug discovery and finding off-label uses of existing drugs. Brown’s lab works on creating new computer models that make drug discovery faster and more reliable. Below is a condensed and edited version of the interview.

Let’s start with the big picture. How is AI changing biomedical research and drug discovery, and what is the potential we are talking about?

Skolnick: The upside, potentially, is very large. One of the frustrating things about drug discovery is that, in spite of the fact that the people doing it are extraordinarily intelligent and have done an extraordinarily good job, the success rate is very low. About 1 in 5 drugs will have negative health effects that outweigh its benefits. Of the ones that pass, roughly half don’t work.

In drug development, there are several key issues: Can you predict which target is driving a particular disease? Once this target is identified, how can you guarantee the drug is going to work and isn’t simultaneously going to kill you?

These are outstanding problems in drug discovery in which AI can play an important, though not 100% guaranteed, role. Unlike us, AI can look at basically all available knowledge. On a good day it makes strong and true connections called “insights,” and on a bad day it does what is called “hallucinating” and sees things that are weak and probably false.

At the end of the day, many diseases do not have a cure. Most diseases are maintained, such as high cholesterol or autoimmune conditions. A treatment for cancer might buy you five years, and now you’re in Stage 4 and you’ve exhausted all the standard care drugs. AI can play a role to suggest alternatives where there are none.

Let’s give some basic definitions here. When we use the word drug, we’re talking about a wide range of therapies. Can you explain the range – we’ve got small molecule drugs, biologics, gene therapies, cell therapies.

Brown: We have fairly large molecules in our bodies called proteins. They are like machines that carry out specific functions and interact with one another. Oftentimes, when we’re trying to treat disease, we’re trying to alter functions of specific proteins. Many drugs, like aspirin and Tylenol, are small molecules that can fit into a protein and change its function. Fundamentally, drugs don’t have to just interact with proteins, but this is a major way in which our current repertoire of medications work.

There are also proteins that act like drugs, such as antibodies. When you receive a vaccine for a virus, your body is basically given instructions on how to develop antibodies. These antibodies will target some part of that virus. Your body is creating these big molecules, much bigger than aspirin, to go and interact with foreign proteins in a different way. Gene therapy is a larger step beyond that.

So these modalities – molecule, protein, antibody or gene – are very different types of molecules. They have different scales and rules, so the way you approach designing and discovering them various widely.

Can you briefly explain artificial neural networks, and what the “deep” in deep learning means?

Skolnick: AlphaFold, developed by DeepMind, involved understanding how neural networks worked. They built a network with a lot of inputs, which are stimuli, and outputs with different weights, similar to how your brain actually works. These simple connections, or neurons, have reinforcement learning.

They also created sophisticated neural networks, such as transformers, which do specific things like a special-purpose tool that can learn, and they added a mechanism called “attention,” which amplifies critical details. Super neural networks with transformers is what we call deep learning. These now have literally billions, if not trillions, of parameters.

Essentially, these machines can learn higher order correlations between events, meaning the patterns of conditional interactions that depend on the properties of multiple things simultaneously. In these higher order correlations, AI has the potential to see previously unknown things that are embedded in petabytes (a unit of data equivalent to half of the contents of all U.S. academic research libraries of biological data.

AlphaFold, which predicts three-dimensional, bioactive forms of a protein, has millions of sequences and a couple of hundred thousand structures. It can tell you, based on a particular pattern, what small molecule to design that sticks to a protein to induce some kind of structural shift.

How is this technology being used in biomedical research to understand molecular dynamics or, essentially, the biological processes involved in health and disease?

Brown: In 2013, there was a Nobel Prize for molecular dynamics simulations, computational tools that help you understand the motions of molecules as they move according to physics. There’s a huge body of scientific research built around those ideas.

AI and deep learning are large right now, but it’s worth mentioning that for the last decade and a half, people have been using much smaller machine learning algorithms to help design drugs. A lot of the ideas, such as [using machine learning for virtual screening], are not new and have been in practice for a while.

With AlphaFold’s technologies to help people design proteins and predict their structure, we’ve changed how we think about a lot of these problems. We have this new repertoire of approaches to build ideas around and to start thinking about drug discovery.

From 20 years ago to now, what has today’s AI technology done in terms of scale of change in this process?

Skolnick: A lot of diseases, like cancers, are caused by a collection of malfunctioning proteins. AI now allows us to start to think conceptually about how these diseases are organized and related to each other.

Diseases tend to co-occur. For example, if you have hyperthyroidism, you’re very likely to develop Alzheimer’s. Kind of weird, right? We can look at pieces, but AI can look at all the information, integrate the collective behavior and then identify common drivers. This allows you to construct disease interrelationships which offer the possibility of broad spectrum treatments that could treat whole collections of diseases rather than narrow-spectrum treatments.

Relatedly, AI also can help us understand disease trajectories. Diseases that tend to co-occur often present themselves consecutively. You have disease 1, it gives you disease 2, then gives you disease 3. This suggests that if you go back to the root with disease 1, you may be able to stop a whole bunch of stuff. You can’t analyze millions of trajectories and millions of data without a tool, so you couldn’t do this before.

This holds a lot of promise, but one also must be careful not to overpromise. It will help, it will accelerate, but it is not a substitute yet for real experiments, real clinical validation and trials.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

“A small vial of genetically engineered cells can contain multiple millions of dollars’ worth of intellectual property and require several years of work to develop,” said Corey Wilson, a professor in Georgia Tech’s School of Chemical and Biomolecular Engineering (ChBE). “Accordingly, the protection of high-value engineered cell lines has become critically important to the biotechnology industry.”

Wilson and his research team have published their findings in Science Advances demonstrating the effectiveness of their new biological security technology, known as GeneLock™, in protecting high-value engineered cell lines.

GeneLock is a cybersecurity-inspired technology that protects valuable genetic material directly at the DNA level. To demonstrate its strength, Wilson’s team conducted what they describe as a first-of-its-kind biohackathon, detailed in the new paper, to simulate unauthorized access. 

“GeneLock greatly improves our ability to protect high-value engineered cell lines by expanding security from the lab environment to the genetic level,” Wilson said.

Economic Impact

What are the stakes? Estimates place the global market for high-value genetic materials at more than $1.5 trillion, projected to reach $8 trillion by 2035. The use of these materials ranges from advanced medicines and proprietary research enzymes to specialty chemicals and sustainable materials.

Currently, the protection of high-value cell lines depends on physical safeguards such as restricted lab access and secure facilities, Wilson explained.

“The key weakness of physical security measures is once circumvented, there are typically no measures in place to protect valuable cells from theft, abuse, or unauthorized use,” Wilson said. 

“Once a sample leaves the building, the DNA it carries typically remains fully functional. This is like placing an unlocked cellphone in a desk drawer. Anyone who gains access to the drawer can view sensitive content on the phone­­­­­­­—or in this case will have full access to the valuable cell line.”

Genetic Passcode Protection

The GeneLock biological security technology developed by Wilson and his team places a passcode on engineered cells, akin to those used on ATM machines and protected cellphones.

Instead of leaving a valuable gene in readable form, the team scrambles the DNA sequence of interest. The scrambled genetic asset remains in a nonfunctional state unless the living cell where it resides receives the correct sequence of chemical inputs. Those inputs act as a molecular passcode.

“Only the right combination, delivered in the right order, rearranges the DNA into a working form,” Wilson said.

Biohackathon Security Test

To evaluate the technology, the researchers organized a blue team and a red team in what they describe as an ethical biohackathon. The blue team designed the encrypted DNA sequence, while the red team was challenged to discover the correct chemical passcode through experimentation in a gray box exercise, meaning the red team had partial knowledge of the system but did not have access to the internal designs. 

“This approach for testing security strength is commonly used in cybersecurity,” Wilson explained. 

The blue team engineered the system inside Escherichia coli, or E. coli, a bacterium widely used in biotechnology. The protected asset was a fluorescent protein gene selected as a measurable stand-in for commercially valuable targets. When the correct chemical sequence was applied, the fluorescence turned on. Without the correct passcode, the gene remained scrambled and the cells could not fluoresce green. 

“In practice, most DNA sequences produce valuable proteins or chemicals that are essentially invisible to the human eye, requiring specialized devices or experiments to observe,” Wilson said. “If the biohackathon were conducted with a standard commercially valuable target, the penetration testing would have taken more than 10 times longer to complete, years instead of months.”

The biohackathon results showed a dramatic reduction in risk. GeneLock reduced the probability of unlocking the genetic asset by random search to about 1 in 85,000 (a 0.001% chance), assuming the unauthorized user had access to the required chemical inputs.

Without access to those inputs, “the likelihood of success by chance becomes effectively negligible,” said Dowan Kim (Georgia Tech PhD 2024), co-lead author of the study.

Commercial Uses and What’s Next 

Although the researchers used a non-commercial fluorescent protein as a test case, the implications extend much further. Many biotechnology companies rely on proprietary engineered strains. New England Biolabs, for example, produces more than 265 non-disclosed enzymes in E. coli, each representing a high-value cell line. 

Protein-based drugs are also manufactured in living cells, and proprietary metabolic pathways are used to produce specialty chemicals, bioplastics, and high-value ingredients. 

“In each case, the genetic blueprint inside the cell represents intellectual property that can be protected by our technology,” said Ishita Kumar, a PhD candidate in ChBE and co-lead author of the study.

While the team’s current focus is on protecting intellectual property in the form of high-value cells, future iterations aim to strengthen biological security more broadly. 

“We are currently developing protection measures to mitigate unauthorized use or release of sensitive cell lines that can be potentially hazardous to human health or the environment,” Wilson said.

“As it stands, GeneLock represents an important shift in biological security, enabling, for the first time, protection of valuable cells at the genetic level, even after physical security measures have been bypassed,” he added. 

The work is already moving toward commercialization. The team filed a provisional patent application with the U.S. Patent and Trademark Office in February 2026 and is forming a company to deploy the technology.

This research was funded by a grant from the National Science Foundation.

CITATION:

Dowan Kim, Ishita Kumar, Mohamed Hassan, Luisa F. Barraza-Vergara, Christopher A. Voigt, and Corey J. Wilson, “Protecting cells at the genetic level and simulating unauthorized access via a biohackathon,” Science Advances, 2026.

Artificial intelligence has been touted as the most transformative technology of our time. With only a few years of mainstream use, it’s changed how we work and communicate, generated billions of dollars in investments, and sparked global debate. But according to leading neuroethics expert Karen Rommelfanger, the race isn’t over yet. 

“Can you think of a more transformative technology than one that intervenes with the fundamental organ that drives your experience in the world?” 

That fundamental organ is the brain.  

Technologies interfacing directly with the brain have been reserved for treating severe injury or disease for decades. Now, neurotechnology is expanding into brain-responsive wearables meant to enhance, augment, and monitor everyday life. As these technologies accelerate and AI is incorporated, the question is no longer if neurotechnology will transform society, but how — and who will shape the boundaries. 

These are some of the questions on which Karen Rommelfanger has built her career. Trained as a biomedical researcher and neuroscientist, Rommelfanger went on to found the Institute for Neuroethics, the world’s first think and do tank devoted entirely to neuroethics, public engagement, and policy implementation.  

“The brain is special; it’s central to who we are,” says Rommelfanger, who was also an inaugural recipient of the Dana Foundation Neuroscience and Society Award. “And that means when you intervene with the brain, there are unique responsibilities. The field of neuroethics addresses things like: How do you ensure mental privacy? How do you protect free will? How do you ensure that people have the power to be narrators of their own lives and their cognitive experience?” 

Now, Rommelfanger is joining Georgia Tech’s Institute for Neuroscience, Neurotechnology, and Society (INNS) as a professor of the practice, where she will work to further embed neuroethics into Georgia Tech’s research and technology development ecosystem. 

“Georgia Tech is producing the next generation of neurotechnologists, and Karen’s expertise will help ensure we’re preparing them to think about societal impact as deeply as they think about the technical and scientific aspects of their work,” says Christopher Rozell, executive director of INNS. “Her leadership strengthens the Institute in exactly the way this moment in neurotechnology demands.”  

“Georgia Tech has many, many ways that it leads in the technology ecosystem. But one of the powerful, unique ways it can lead is through neurotechnology,” says Rommelfanger. “I hope that the INNS, given its unique mandate for neuroscience, neurotechnology, and society, can be a lighthouse for these types of conversations.” 

Neuroethics by Design 

“The topic of the Suddath Symposium changes every year, which allows the Georgia Tech research community to annually learn about recent advances on a specific topic from across the immense fields of bioengineering and bioscience,” said Nicholas Hud, Regents’ Professor in the School of Chemistry and Biochemistry and Associate Director of IBB.

The symposium also included presentation of the 2026 Suddath Award, which recognizes outstanding graduate research. This year’s award was presented to Myeongsoo Kim, a Ph.D. candidate in the Bioengineering Graduate Program, for his work at the intersection of cell engineering, cancer treatment, and biomedical imaging. The award is presented each year by members of the Suddath family, including Vincent Suddath, grandson of Bud and a current freshman at Georgia Tech majoring in mathematics.

The symposium and award honor the legacy of F. L. “Bud” Suddath and his lasting contributions to the Institute and the wider Georgia Tech research community.

“Bud was influential in promoting the growth of bioscience research at Georgia Tech, efforts that helped establish IBB in the 1990s,” Hud said. “Bud’s research interests were at the forefront of structural biology, a field that laid the foundation for much of what we know today about biology at the molecular level. It’s fitting that we honor Bud’s contributions by annually providing the Georgia Tech community with the opportunity to learn about research on a timely topic within the biological sciences.”

Symposium co-chairs Tara Deans and Mark Styczynski said that in addition to upholding the legacy of Bud Suddath, the event also provides a unique setting and opportunity for both established researchers and trainees to interact over the course of the two day event. The intimate format of the symposium, which is limited to approximately 100 attendees, and the annual selection of a different interdisciplinary topic sets it apart from other symposia.

“The Suddath Symposium is an amazing opportunity to bring multiple world-class researchers right to our trainees’ front door, to hear about their work and connect with them in a small setting that you can’t really find at most conferences,” said Styczynski, who is a professor in the School of Chemical and Biomolecular Engineering. “We are really grateful to IBB and the Suddath family for supporting this unique event.”

Deans, who is an associate professor in the Wallace H. Coulter Department of Biomedical Engineering, highlighted how this year’s theme reflects a broader shift in the field.

“This year’s focus on biomedical applications of synthetic biology highlights a major inflection point in the field: the transition from proof-of-concept systems to human health-relevant technologies,” she said. “The theme also reflects increasing convergence across disciplines; synthetic biology is no longer operating in isolation, but it is deeply intertwined with immunology, machine learning, diagnostics, and clinical translation. Addressing real-world biomedical problems requires this kind of integration, and the symposium captured that shift very clearly.”

The Suddath Symposium annually serves as a cornerstone event for Georgia Tech’s bioengineering and bioscience community — connecting researchers, honoring scientific legacy, and spotlighting the next generation of scientific innovation.

Health and medicine is more than just biological – societal forces can get under your skin and cause illness. Medical sociologists like me study these forces by treating society itself as our laboratory. Health and illness are our experiments in uncovering meaning, power and inequality, and how it affects all parts of a person’s life.

For example, why do low-income communities continue to have higher death rates, despite improved social and environmental conditions across society? Foundational research in medical sociology reveals that access to resources like money, knowledge, power and social networks strongly affects a person’s health. Medical sociologists have shown that social class is linked to numerous diseases and mortality, including risk factors that influence health and longevity. These include smoking, overweight and obesity, stress, social isolation, access to health care and living in disadvantaged neighborhoods.

Moreover, social class alone cannot explain such health inequalities. My own research examines how inequalities related to social class, race and gender affect access to autism services, particularly among single Black mothers who rely on public insurance. This work helps explain delays in autism diagnosis among Black children, who often wait three years after initial parent concerns before they are formally diagnosed. White children with private insurance typically wait from 9 to 22 months depending on age of diagnosis. This is just one of numerous examples of inequalities that are entrenched in and deepened by medical and educational systems.

Medical sociologists like me investigate how all of these factors interact to affect a person’s health. This social model of illness sees sickness as shaped by social, cultural, political and economic factors. We examine both individual experiences and societal influences to help address the health issues affecting vulnerable populations through large-scale reforms.

By studying the way social forces shape health inequalities, medical sociology helps address how health and illness extend beyond the body and into every aspect of people’s lives.

Origins of Medical Sociology in the US

Medical sociology formally began in the U.S after World War II, when the National Institutes of Health started investing in joint medical and sociological research projects. Hospitals began hiring sociologists to address questions like how to improve patient compliance, doctor-patient interactions and medical treatments.

However, the focus of this early work was on issues specific to medicine, such as quality improvement or barriers to medication adherence. The goal was to study problems that could be directly applied in medical settings rather than challenging medical authority or existing inequalities. During that period, sociologists viewed illness mostly as a deviation from normal functioning leading to impairments that require treatment.

For example, the concept of the sick role – developed by medical sociologist Talcott Parsons in the 1950s – saw illness as a form of deviance from social roles and expectations. Under this idea, patients were solely responsible for seeking out medical care in order to return to normal functioning in society.

In the 1960s, sociologists began critiquing medical diagnoses and institutions. Researchers criticized the idea of the sick role because it assumed illnesses were temporary and did not account for chronic conditions or disability, which can last for long periods of time and do not necessarily allow people to deviate from their life obligations. The sick role assumed that all people have access to medical care, and it did not take into account how social characteristics like race, class, gender and age can influence a person’s experience of illness.

Parsons’ sick role concept also emphasized the expertise of the physician rather than the patient’s experience of illness. For example, sociologist Erving Goffman showed that the way care is structured in asylums shaped how patients are treated. He also examined how the experience of stigma is an interactive process that develops in response to social norms. This work influenced how researchers understood chronic illness and disability and laid the groundwork for later debates on what counts as pathological or normal.

In the 1970s, some researchers began to question the model of medicine as an institution of social control. They critiqued how medicine’s jurisdiction expanded over many societal problems – such as old age and death – which were defined and treated as medical problems. Researchers were critical of the tendency to medicalize and apply labels like “healthy” and “ill” to increasing parts of human existence. This shift emphasized how a medical diagnosis can carry political weight and how medical authority can affect social inclusion or exclusion.

The critical perspective aligns with critiques from disability studies. Unlike medical sociology, which emerged through the medical model of disease, disability studies emerged from disability rights activism and scholarship. Rather than viewing disability as pathological, this field sees disability as a variation of the human condition rooted in social barriers and exclusionary environments. Instead of seeking cures, researchers focus on increasing accessibility, human rights and autonomy for disabled people.

A contemporary figure in this field was Alice Wong, a disability rights activist and medical sociologist who died in November 2025. Her work amplified disabled voices and helped shaped how the public understood disability justice and access to technology.

Structural Forces Shape Health and Illness

By focusing on social and structural influences on health, medical sociology has contributed significantly to programs addressing issues like segregation, discrimination, poverty, unemployment and underfunded schools.

For example, sociological research on racial health disparities invite neighborhood interventions that can help improve overall quality of life by increasing the availability of affordable nutritious foods in underserved neighborhoods or initiatives that prioritize equal access to education. At the societal level, large-scale social policies such as guaranteed minimum incomes or universal health care can dramatically reduce health inequalities.

Medical sociology has also expanded the understanding of how health care policies affect health, helping ensure that policy changes take into account the broader social context. For example, a key area of medical sociological research is the rising cost of and limited access to health care. This body of work focuses on the complex social and organizational factors of delivering health services. It highlights the need for more state and federal regulatory control as well as investment in groups and communities that need care the most.

Modern medical sociology ultimately considers all societal issues to be health issues. Improving people’s health and well-being requires improving education, employment, housing, transportation and other social, economic and political policies.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

A team of researchers led by Ankur Singh, the Carl Ring Family Professor in the George W. Woodruff School of Mechanical Engineering and professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, has been awarded up to $6 million from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense to accelerate the development of medical countermeasures (MCMs) against deadly biological threats that endanger public health, national security, and warfighters.

DTRA’s mission is to provide solutions that enable the Department of Defense, the U.S. government, and international partners to deter strategic threats. A key priority is advancing new or improved MCMs that can be deployed before or after exposure to biological or chemical agents.

Singh’s multi-year project, Systematic Human Immune Engineering for Lethal Disease (SHIELD) Countermeasures, aims to create a threat-agnostic platform that transforms how respiratory pathogens and toxins are studied. The platform is designed to speed up the discovery, development, and production of immune-based countermeasures.

Singh leads a collaborative team that includes Cornell University’s Matthew DeLisa and Stanford University’s Michael Jewett. Together, they will integrate immune-engineering technologies with advanced cell-free protein synthesis platforms to discover and manufacture protein-based MCMs. Cell-free protein synthesis is a laboratory technique that efficiently produces proteins without relying on living cells, which can be unpredictable and technically demanding when it comes to expressing complex or toxic proteins and scaling production quickly. The team expects the SHIELD Countermeasures platform to reduce the time and cost of MCM development by more than tenfold.

“The foundational science and cutting-edge tools we develop will ignite future discoveries, ensuring a robust pipeline of advanced protein-based MCMs for chemical and biological defense,” said Singh, who also directs the Center for Immunoengineering at Georgia Tech. “This will significantly enhance national security and equip our warfighters with next-generation biodefense capabilities."

Traditional animal models often fail to accurately replicate human immune responses, and standard tissue cultures lack the complexity required to study how immune cells interact with pathogens. In contrast, human immune organoids and immune-competent devices — built from human cells — are emerging as groundbreaking research tools. These systems recreate key immune features, such as lymph nodes and mucosal environments, within three-dimensional or microengineered platforms.

“Many organoid and engineering devices, often called organ-on-chip platforms, lack immune integration,” Singh said. “Because immunity sits at the center of human health, these limitations have broad consequences. Immune-competent organ-on-chip platforms extend this concept by combining human cells with microfluidic engineering that simulates blood flow, tissue barriers, and chemical gradients.”

Singh has previously published studies on a synthetic human immune chip and an immunocompetent lung on a chip, and has also teamed up with DeLisa previously to use synthetic immune organoids for immuno-profiling antibacterial MCMs.

“It’s about being able to test far larger numbers of candidate protein-based MCMs in a single experiment—and to do it much faster,” DeLisa said. “Cell-free systems allow us to produce MCMs at unprecedented speed and scale, but traditional evaluation methods can’t keep up with those numbers. By combining cell-free MCM production with immune organoid technology, we can assess the potency of dozens or even hundreds of candidates at a time and characterize the resulting immune responses within just a few days.”

By integrating immune cells with tissues such as lung, gut, skin, or vascular systems, these devices allow scientists to observe immune responses in real time, including cell migration, inflammation, and interactions with pathogens or therapeutics. As biological threats evolve, the development and deployment of immune-competent platforms will be critical for rapid, effective countermeasures.

DTRA’s investment in Singh’s work highlights the urgent national priority of strengthening U.S. biodefense capabilities. The SHIELD Countermeasures platform and its cutting-edge technologies promise to transform the nation’s response to biological threats and help safeguard communities from biological and chemical attacks.

A philanthropic gift from the family of J.P. Singh is helping researchers at Georgia Tech push the boundaries of biomedical innovation.  

The new study is the first to visualize mosquito flight patterns and provides hard data for improving capture and control strategies. In addition to being a nuisance, mosquitoes transmit diseases such as malaria, yellow fever, and Zika, which cause more than 700,000 deaths every year.

“It’s like a crowded bar,” said David Hu, a professor in Georgia Tech’s George W. Woodruff School of Mechanical Engineering and the School of Biological Sciences, with an adjunct appointment in the School of Physics. “Customers aren’t there because they followed each other into the bar. They’re attracted by the same cues: drinks, music, and the atmosphere. The same is true of mosquitoes. Rather than following the leader, the insect follows the signals and happens to arrive at the same spot as the others. They’re good copies of each other.”

Read more and watch: 
Georgia Tech College of Engineering newsroom and The Conversation

Amino acids also play a critical role commercially where they are manufactured and added to pharmaceuticals, dietary supplements, cosmetics, animal feeds, and industrial chemicals — an energy-intensive process leading to greenhouse gas emissions, resource consumption, and pollution.

A landmark new system developed at Georgia Tech could lead to an alternative: a commercially scalable, environmentally sustainable method for amino acid production that is carbon negative, using more carbon than it emits.

The breakthrough builds on a method that the team pioneered in 2024 and solves a key issue – increasing efficiency to an unprecedented 97% and reducing the bioprocess cost by over 40%. It’s the highest reported conversion of CO2 equivalents into amino acids using any synthetic biology system to date.

Published in the journal ACS Synthetic Biology, the study, “Cell-Free-Based Thermophilic Biocatalyst for the Synthesis of Amino Acids From One-Carbon Feedstocks,” was led by Bioengineering Ph.D. student Ray Westenberg and Professor Pamela Peralta-Yahya, who holds joint appointments in the School of Chemistry and Biochemistry and School of Chemical and Biomolecular Engineering. The team also included Shaafique Chowdhury (Ph.D. ChBE 25) and Kimberly Wennerholm (ChBE 23); alongside University of Washington collaborators Ryan Cardiff, then a Ph.D. student and now a Chain Reaction Innovations Fellow at Argonne National Laboratory, and Charles W. H. Matthaei Endowed Professor in Chemical Engineering James M. Carothers; in addition to Pacific Northwest National Laboratory Synthetic Biology Team Leader Alexander S. Beliaev.

"This work shifts the narrative from simply reducing carbon emissions to actually consuming them to create value,” says Peralta-Yahya. “We are taking low-cost carbon sources and building essential ingredients in a truly carbon-negative process that is efficient, effective, and scalable.”

Heat-Loving Organisms

The work builds on the cell-free technology the team used in their earlier study. “Previously, we discovered that a system that uses the machinery of cells, without using actual living cells, could be used to create amino acids from carbon dioxide,” Peralta-Yahya explains. “But to create a commercially viable system, we needed to increase the system’s efficiency and reduce the cost.”

The team discovered that bits of leftover cells were consuming starting materials, and — like a machine with unnecessary gears or parts — this limited the system’s efficiency. To optimize their “machine,” the team would need to remove the extra background machinery.

"Leftover cell parts were using key resources without helping produce the amino acids we were looking for,” says Peralta-Yahya. “We knew that heating the system could be one way to purify it because heat can denature these components.”

The challenge was in how to protect the essential system components from the high temperatures, she adds. “We wondered if introducing enzymes produced by a heat-loving bacterium, Moorella thermoacetica, might protect our system, while still allowing us to denature and remove that inefficient background machinery.”

The results were astounding: after introducing the enzymes, heating and “cleaning” the system, and letting it cool to room temperature, synthesis of the amino acids serine and glycine leaped to 97% yield — nearly three times that of the team’s previous system.

Scaling for Sustainability

To make the system viable for large-scale use, the team also needed to reduce costs. “One of the most costly components in this system is the cofactor tetrahydrofolate (THF),” Peralta-Yahya shares. “Reducing the amount of THF needed to start the process was one way to make the system more inexpensive and ultimately more commercially viable.”

By linking reaction steps so waste from one step fueled the next, the team devised a method to recycle THF within the system that reduces the amount of THF needed by five-fold — lowering bioprocessing costs by 42%.

“This decrease in cost and increase in yield is a critical step forward in creating a method with real potential for use in industry and manufacturing,” Peralta-Yahya says. “This system could pave the way for moving this carbon-negative technology out of the lab and onto the continuous, industrial scale."

Funding: The Advanced Research Project Agency-Energy (ARPA-E); U.S. Department of Energy; and the U.S. Department of Energy, Office of Science, Biological and Environmental Research Program.

DOI: https://doi.org/10.1021/acssynbio.5c00352

The Advanced Technology Development Center (ATDC) in Georgia Tech’s Office of Commercialization announced two of its health technology (HealthTech) portfolio companies, Nephrodite and OrthoPreserve, earned the designation. 

Achieving this rare milestone underscores the caliber of founders, science, and support in ATDC’s 30-company HealthTech portfolio, the incubator’s largest focus area. It’s also a win for Georgia because it reflects the strength of the state’s health innovation ecosystem. 

“This designation is one of the strongest signals the FDA gives that a technology could change the standard of care,” said Greg Jungles, HealthTech catalyst at ATDC. “For ATDC to have two in the same year is remarkable.” 

The Breakthrough Device Program doesn’t waive evidence requirements, but it accelerates learning with the FDA, ATDC’s Jungles said. “That means shorter response times, more frequent meetings, and prioritized review. Teams avoid dead ends and align earlier on study designs and endpoints.” 

For the founders of both startups, their technologies come one step closer to moving their innovations to market. Nephrodite’s technology improves the lives of dialysis patients. OrthoPreserve’s device addresses challenges faced by those who suffer from chronic knee pain. 

Nephrodite: Advancing Continuous Artificial Kidney Technology 

Dr. Nikhil Shah and Dr. Hiep Nguyen, cofounders of Nephrodite, aim to improve care for dialysis patients with end-stage kidney disease who need transplants. These patients often spend three to four hours in a dialysis clinic up to three times a week. Being tethered to stationary machines with needles drawing blood via arm grafts complicates everyday activities — from work tasks to the ability to travel. 

Dialysis addresses chronic kidney disease, which means kidneys no longer work properly. The treatments filter out toxins, waste, and other fluids in the blood. Kidney disease costs Medicare $124.5 billion every year, according to the Centers for Disease Control and Prevention. And those costs are expected to rise because of increasing rates of kidney failure and chronic kidney disease. 

“Dialysis, while lifesaving when it was pioneered in 1952, is incredibly burdensome,” Shah said. Besides being a long process that keeps the patient in a fixed location, it’s physically tiring. “Taking out your blood continually many, many times over, and over the course of four hours is the equivalent of running the Boston Marathon, hitting the finish line, and then someone saying, ‘You're not done; go do it again,’ ” he said. 

A surgeon by training, with expertise in transplantation and oncology, Shah is also an adjunct associate professor in Tech’s School of Interactive Computing. He worked with Nguyen to develop a continuously functioning mechanical artificial kidney, leading to Nephrodite’s formation. 

The FDA’s breakthrough designation on its artificial kidney allows the company to pursue approvals to begin tests in human trials. 

The company traces its beginnings to a German aerospace facility outside Munich, where Nguyen and Shah watched engineers demonstrate a pediatric artificial heart — the Berlin Heart. 

“That’s how we got started,” Shah said. “Seeing an artificial heart that led us to think about doing this for kidneys — because the kidney space has been largely ignored for 70 years.” 

Backed by a German federal grant, Nephrodite grew, moving from Germany to Boston, Massachusetts, then to Austin, Texas, before calling Atlanta home. The company joined ATDC and tapped into other Georgia Tech programs. This included the Center for MedTech Excellence and the Georgia Manufacturing Extension Partnership. Nephrodite also drew on student talent as the researchers quietly worked on their continuous mechanical artificial kidney. 

Nephrodite began interviewing patients to find out what they wanted the artificial kidney needed to solve. 

They learned patients want the ability to be mobile. Patients also desire an alternative therapy to large needles being inserted into arm grafts because the injection sites are prone to infection and the grafts can fail. In addition, the process can be painful and disfiguring. Finally, patients want a quality of life independent of machines. 

“Those quality-of-life needs, especially being free and mobile, were absolutely universal,” Shah said.  

Nephrodite began developing the technology to build its device — a filter surgically implanted in the pelvis area. 

“We developed an implant designed to run constantly, connected to larger blood vessels in the pelvis to avoid arm graft failures, and paired with an external interface that lets patients sleep at night while the system removes toxins and excess fluid,” Shah explained. 

The device also has built-in sensors, with data uploaded to the cloud, enabling medical care teams to remotely monitor their patients while freeing patients from frequent in-clinic visits. 

Shah said Nephrodite’s device could restore everyday independence, while potentially lowering infection risk. 

“It's like having an actual kidney, but without all the issues of an unhealthy one,” Shah said.  

OrthoPreserve: Innovating a Minimally Invasive Meniscus Implant 
 
OrthoPreserve’s technology aims to address issues from people have with their meniscus, the C‑shaped piece of cartilage in a knee joint that acts as a shock absorber between the thigh bone and shin bone. 

Though patients undergo a now-routine surgery to address it, incomplete recoveries are also common. An estimated quarter of patients later experience recurring knee pain. No FDA-approved implant currently exists for this population. Now, OrthoPreserveis developing a minimally invasive, artificial meniscus implant to restore cushioning, relieve pain, and delay — or even prevent — knee replacement for some patients. 

“There are a million meniscus surgeries every year, and 25% of those patients still live with recurring pain,” said Jonathan Schwartz, OrthoPreserve’s founder and CEO. 

Patients can face daily pain from ordinary activities, such as prolonged standing or walking a dog. Other activities like jogging and recreational sports can trigger flares that can lead to swelling and prolonged discomfort, Schwartz said. “Those patients have no reliable options today,” he said. “We’re building a minimally invasive implant to restore cushioning and help people get back to the activities they love.” 

OrhoPreserve’s durable implant restores cushioning, and it could help people return to normal activities and delay invasive knee replacement. Along with this comes potential cost and recovery benefits for the healthcare system.   

Schwartz created the implant as his Georgia Tech master’s thesis in the lab of David Ku in the Lawrence P. Huang Endowed Chair for Engineering Entrepreneurship and Regents' Professor in the George W. Woodruff School of Mechanical Engineering. After industry experience, Schwartz returned to further develop the technology, building on Georgia Tech’s translational expertise 

OrthoPreserve has completed mechanical testing and a successful study. The company is raising a $2 million seed to complete validations and begin human trials, which Schwartz expects to start in 18 months. 

“The FDA breakthrough designation validates that nothing like this technology exists, and that it has the potential to disrupt the standard of care,” Schwartz said, adding the U.S.’ market opportunity is roughly $1.5 billion. “We finally have a minimally invasive option to bridge the gap between meniscus surgery and knee replacement.” 

What FDA Breakthrough Designation Means for ATDC’s HealthTech Startups 

Having a faster and clearer path is a derisking milestone for investors who are evaluating capital intensive medical device technologies, Jungles said. 

“This breakthrough device designation is a really big deal for medical device companies,” Jungles said, adding that startups often fear navigating the FDA approval process. “But this designation adds to the legitimacy of their technologies and the problemsthey are solving. The designation will help them get to market faster, assuming their data continues to meet expectations.” 

ATDC launched its HealthTech vertical in 2018, which is now sponsored by Catalyst by Wellstar ATDC’s HealthTech portfoilo companies include medical devices, biotech, and digital health, among other segments. 

ATDC’s Role in Accelerating HealthTech Innovation 

Nephrodite and OrthoPreserve’s founders noted ATDC’s coaching and programming as critical in navigating fundraising and regulatory milestones. Another factor, they said, was ATDC’s connection to Georgia Tech’s labs and facilities and prototyping support and clinical advisors from across metro Atlanta.  

“We meet with ATDC coaches every two to four weeks to troubleshoot and plan,” Schwartz said. “Having that level of seasoned guidance, all without consultant-level costs, has been huge.” 

Jungles added that two Breakthrough device designations in the same year reflects ATDC’s selection rigor, noting he’s evaluated hundreds of technologies since the HealthTech vertical launched. 

“It reflects the caliber of the companies in ATDC, specifically in the medical device space,” Jungles said. “It’s the strength of their teams, the persistence of the founders, and the collaboration of the ecosystem in Georgia and Atlanta.” 

“I’m thrilled to see Professor Sherrill tackle this role for the coming 5 years. He understands the rapidly evolving opportunities to apply AI and data science approaches to the diversity of research conducted by Georgia Tech faculty and students, and has a strong agenda to help our researchers make the most of this explosive change in the research landscape.” Said V.P. of Interdisciplinary Research, Julia Kubanek. “He also has deep experience with team building and management which will position IDEaS favorably.”

As executive director, Sherrill will guide IDEaS’ current initiatives, which include the Microsoft CloudHub program that supports innovative applications in Generative Artificial Intelligence, and provide oversight and support for the joint College of Computing / IDEaS Center for Artificial Intelligence in Science and Engineering (ARTISAN), which provides  Georgia Tech faculty and research engineers expert support staff, needed cyberinfrastructure, software resources, and advice to assist faculty with projects using large data sets or using AI and machine learning to drive discovery.

Sherrill will also the lead the launch of a new strategic vision, emphasizing the Georgia Tech research community’s expertise in the development of AI and ML techniques and their application to problems in science and engineering, high performance computing, and academic software. Sherrill will focus on internal and external partnerships at IDEaS, creating new collaborative efforts in areas such as economics, policy, and the arts and humanities. He will also work to strengthen current connections across Georgia Tech’s Colleges, Interdisciplinary Research Institutes (IRIs), and the Georgia Tech Research Institute (GTRI).

“It’s a great honor to be named the next executive director of IDEaS,” said Sherrill.  “Georgia Tech has world-class faculty and students, and an unparalleled spirit of collaboration.  By bringing together faculty from across campus and working together with some of the amazing student groups, we can leverage the power of AI to accelerate our research and maximize our impact.  IDEaS will continue to run upskilling workshops to help our campus keep pace with the rapid changes in AI.”

Sherrill is an active promoter of education in computational quantum chemistry, as well as a strong voice for the benefits of open-source software for research acceleration. He was named Outreach Volunteer of the Year by the Georgia Section of the American Chemical Society in 2017, and he is the lead principal investigator of the Psi open-source quantum chemistry program.

Sherrill earned a B.S. in chemistry from MIT in 1992 and a Ph.D. in chemistry from the University of Georgia in 1996. From 1996-1999 Sherril was an NSF Postdoctoral Fellow at the University of California, Berkeley.

Sherrill is Fellow of the American Association for the Advancement of Science (AAAS), the American Chemical Society, and the American Physical Society, and he has been Associate Editor of the Journal of Chemical Physics since 2009. Sherrill has received a Camille and Henry Dreyfus New Faculty Award, the International Journal of Quantum Chemistry Young Investigator Award, an NSF CAREER Award, and Georgia Tech's W. Howard Ector Outstanding Teacher Award. In 2023, he received the Herty Medal from the Georgia Section of the American Chemical Society, and in 2024, he was elected to the International Academy of Quantum Molecular Science.

- Christa M. Ernst

“It was a hypothesis. I was the experiment, and the hypothesis was proven true.” 

Can an inner-city student who grew up below the poverty line earn a Ph.D. and make a career in research? In theory, yes.  

The barriers are many. But literature suggests that early exposure to STEM and research opportunities can increase the odds for students in need.  

For Kendreze Holland, the idea of making it to college and earning an advanced degree was a hypothesis. Sure, theoretically it could be done — but in his own home, not everyone had even made it past high school.  

Often, the first question on the way to scientific discovery is: What if? What if a student like Holland received the right help at the right time? What if he was guided along the way by mentors who were leaders in their fields? What if he was given the opportunity to develop professional skills and make valuable connections? 

Holland asked himself: What if he could be the one to prove the hypothesis true? 

Introduction 

Holland grew up in northwest Atlanta, one of seven children raised by a single mother. Being one of so many children, most would struggle to stand out. But Holland always sought to be different.  

“My perpetual intention was to be less of a burden to my mother,” he said. “Since my mother’s education limited her abilities to help with my schoolwork, I went above the call of duty to stand out in academics.” 

His mother’s education was cut short in ninth grade so she could raise her first child, Holland’s older sister, and no one in his family had gone to college. In his mind, he had three career paths to choose from: football, hip hop, or retail.  

“Standing at a solid 5 foot 8, the first would have been difficult,” he joked. “And the latter two were not my calling.” 

Just like his mother, the course of his life changed in his ninth-grade year. For Holland, it began an academic journey he never expected.  

In 2012, he was attending B.E.S.T. Academy, an all-boys public school for grades six through 12 focused on business and STEM. Biology class was just another hour waiting to pass for the 15-year-old Holland, until the day two guest speakers from Georgia Tech walked into the room with “some weird apparatuses and mechanical chopsticks.” 

The two guests used the equipment — gel electrophoresis systems and pipettes — to show the boys what research can look like in real life. 

“This experience sparked within me a drive for science, and it was the first time I realized that I wanted to, and could, attain an advanced scientific degree,” Holland said.  

The two speakers were Manu Platt, a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, and Jerald Dumas, a postdoctoral researcher. Platt and Dumas were there to recruit students for a new program called Project ENGAGES within the Parker H. Petit Institute for Bioengineering and Bioscience (IBB).  

The program was co-founded by Platt and the late Robert M. Nerem, IBB’s founding executive director, to give students like Holland an opportunity to participate in real research projects that would hopefully plant a seed in the next generation of scientists.  

Students come from one of eight partner schools in Atlanta. Once accepted, they are connected to a Georgia Tech graduate student who mentors them and supervises their work, and they get paid to work in their assigned lab for one year.  

Project ENGAGES does more than expose students to STEM concepts and ideas. It equips them with the skills and knowledge to carry out their own independent research projects. They also have opportunities to establish connections with university faculty and industry representatives who can provide career guidance and support. 

Methods 

Though Holland didn’t meet the program’s age requirement in 2012, he applied again the next year and was accepted. During his junior and senior years of high school, he worked in Platt’s lab, where he aided with projects involving proteins, cell cultures, and antibodies.  

“Over the course of those two years, the growth I saw scientifically, professionally, and in maturity, all corroborated my belief that Kendreze was going far, and able to push past whatever goals and obstacles he comes up against,” said Platt, now the director of the Center for Biomedical Engineering Technology Acceleration housed within the National Institute of Biomedical Imaging and Bioengineering.  

Holland's experience sparked a love for science and a career-long connection with Georgia Tech. After high school, he graduated summa cum laude with a degree in chemistry from Georgia State University. As an undergraduate, he stayed connected with Tech and with IBB as a Petit Scholar, a yearlong mentorship program and research experience for top students around Atlanta. 

“I really wanted to stay close to home, and I felt like everything was in my backyard,” he said. “There are many people who come here from other places to Tech because of the great science that is going on. There’s something special about Atlanta, and I’m just getting the best of what I can from it.” 

He credits his time in Project ENGAGES with giving him the confidence and resilience to continue toward his goals. Like many others in the program, he was a first-generation college student with little to no guidance for his academic career. The holistic approach of Project ENGAGES provided professional development opportunities and standardized test preparation to ready him for life in college and beyond. 

“I knew I wanted to go to grad school, but I didn’t know I was going to do all these things,” he said. “Having that one goal sprouted a lot of side quests that just grew into something bigger.” 

After graduating from Georgia State in 2020, Holland was accepted into Georgia Tech’s Bioengineering Graduate Program as a doctoral student. In December 2025, he became the first Project ENGAGES alumnus to successfully defend his dissertation, and he is expected to graduate this spring. 

Lakeita Servance, assistant director of Outreach Initiatives at IBB, was the program manager for Project ENGAGES when Holland was accepted and cheered him on more than 10 years later as he presented his doctoral research. 

“As I sat in that room while he was defending his dissertation and sharing his research with all of us, I still reflected on that boy I saw at 16 years old,” she said. “It was this full circle moment to see him make it all the way back here. The investment we made over a decade ago has paid off in such a large way.” 

Results 

In addition to being the first in his family to go to college and earn an advanced degree, Holland received financial support from the National Science Foundation’s Graduate Research Fellowship Program; was awarded multiple prestigious fellowships, including FORD, GEM, and Herbert P. Haley; landed an internship with 3M Corporate Research Materials Laboratory; and served as a mentor in the Nakatani Research and International Experience for Students. He has published papers, led panel discussions, applied for patents, and presented his research at national conferences.   

“All that stemmed from Project ENGAGES,” he said. “And more importantly, I applied to be a mentor for the ENGAGES program.” 

Holland said some of his most meaningful experiences have come from being able to give back. He has served as a mentor, both formally and informally, to more than half a dozen students, some who come from backgrounds much like his own. 

“I wanted to give back to the program because it poured so much into me. They were able to get me all the way to the Ph.D. level, so I knew that I could use my grind to help other students.” 

Conclusion 

Having proved the hypothesis true, Holland is turning his focus to the future, considering his options in academia and corporate research while he continues to work as a postdoc at Georgia Tech.  

His research in John Blazeck’s lab focuses on cellular engineering using CRISPR gene editing technology to regulate gene profiles, meaning he and other researchers can turn certain genes up and others down to affect the way cells respond. Though he is currently working with yeast cells, he hopes that his research will translate into mammalian cells that could have more clinical applications.  

“In terms of diseases and disorders, you can use it to tune genes to help someone experiencing cancer by helping immune cells or stopping cancer cells from dividing rapidly,” he said. “You can also help other cells to survive longer, and longer cell viability means potentially a patient can survive longer.” 

What began as a presentation in a high school science class has led Holland to a future he never expected. Tequila Harris, professor in the George W. Woodruff School of Mechanical Engineering and co-director of Project ENGAGES, said his story shows others that they can do the same.  

“I believe his achievements will inspire and motivate generations of students to pursue dreams that they may not have known they had. Kendreze Holland has fundamentally shown others that there are multiple pathways to engage in STEM and that opportunities and access to advanced degrees can be attained by those willing to do the work.” 

Holland's story is symbolic of the ultimate goal for Project ENGAGES: to change the lives of talented young people who may never have had the opportunity to succeed.  

“That’s why I was so adamant about getting my Ph.D.,” he said, “to show that one could potentially overcome what they were going through to do something extraordinary.” 

Project ENGAGES is possible thanks to philanthropic support from our generous community: Donate here.

The Georgia Institute of Technology and Augusta University have launched a collaborative effort to boost the city’s medical device innovation ecosystem. 

The new initiative was sparked by ongoing research at Georgia Tech — and a Yellow Jacket connection: when Postdoctoral Research Fellow Hannah Youngblood’s work on exfoliation glaucoma (XFG) was featured by the BrightFocus Foundation, it caught the attention of Jennifer Rucker, an Alabama resident who was diagnosed with XFG several years ago.

Excited that the research could change outcomes for people like her — and proud that it’s happening at her husband Philip Rucker’s, EE 72, alma mater — Jennifer Rucker reached out to Youngblood and her advisor, School of Chemistry and Biochemistry Professor and Kelly Sepcic Pfeil, Ph.D. Chair Raquel Lieberman. 

“As the wife of a Georgia Tech graduate and an individual with pseudoexfoliation glaucoma, I was inspired to support the scientists whose efforts may help me and others,” Jennifer Rucker says. What followed was a meaningful dialogue and a shared sense of purpose — and the creation of the Georgia Tech Glaucoma Research Fund (Wreck Glaucoma! Fund). 

“It meant so much that Jennifer took the initiative to reach out to learn more about our research,” says Lieberman. “Moments like this remind me how deeply meaningful it is to connect with people in the broader community who are navigating glaucoma. Opportunities for such personal connections are rare, but they inspire and further motivate us to achieve our lab’s mission to improve the lives of individuals suffering from blindness diseases.”

A Personal Connection

Youngblood’s interest in glaucoma research also stems from a personal connection: her father was diagnosed with glaucoma as a young adult. Now, Youngblood studies the genetic and molecular factors behind XFG in the Lieberman research lab. 

“XFG is an aggressive form of the disease with no known cure,” Youngblood says. While scientists know that XFG is the result of abnormal accumulation of proteins in the eye, current treatments only address symptoms rather than treating the root cause of the disease.

“We know XFG is driven by protein buildup, but we still don’t know why it happens,” she explains. “My work studying specific genetic variants aims to uncover this.” 

The Genetics of Glaucoma

In particular, Youngblood is researching the role of LOXL1, a protein that plays a role in soft tissue throughout the body, including the eyes.

“Research has shown that people with variants in the genes responsible for this protein are more likely to have XFG,” she says. “That made me curious to see if the variants might be impacting the structure of the LOXL1 protein itself and how those variants might lead to disease.”

Youngblood is currently testing her theory in the lab. “My hope is that new insight into proteins like LOXL1 will bring us closer to treatments that address XFG at its source,” she says. “The new Georgia Tech Glaucoma Research Fund is a tremendous step forward in making that hope a reality.”

Support the Georgia Tech Glaucoma Research Fund

Please visit the Glaucoma Research Fund support page to give to this specific program. To discuss additional philanthropic opportunities, please contact the College of Sciences Development Team: development@cos.gatech.edu

Your investment ensures that these scholars and researchers have world-class resources, facilities, and mentors to excel in this critical work. Thank you for helping us shape the future.

Advancing the frontiers of regenerative medicine means more than pushing scientific boundaries — it means improving and extending human life. The Regenerative Engineering and Medicine Center (REM) is a partnership with Georgia Tech, Emory University, and the University of Georgia (UGA) that supports this mission through inter-institutional collaborations in research in regenerative medicine.  

On Nov. 5 – 6, Georgia Tech hosted the Pediatric Healthcare Innovation Summit 2025 (PHIS), a one-of-a-kind event that brought champions of children’s health together to share knowledge, facilitate collaborative initiatives, and accelerate medical innovation. The summit was co-presented by the Georgia Tech Pediatric Innovation Network (PIN), the International Society for Pediatric Innovation (ISPI), and the FDA-funded Pediatric Device Consortia (PDC).

The event included a tour of the new Arthur M. Blank Hospital, technology showcases, workshops, panel discussions, a poster session, and a pitch competition where companies were awarded funding from the Pediatric Device Consortia. 

“Georgia Tech is committed to advancing medicine, but in particular pediatric medicine, which is normally underfunded compared to adult healthcare,” Georgia Tech President Ángel Cabrera said. “We are committed to playing our part, and we're doing that in partnership with the best organizations, combining our engineering skills with clinical partners who understand the most important needs of children.”

Cabrera was a guest speaker for the event, which took place at two locations across campus: the newly opened Science Square and the Historic Academy of Medicine. He emphasized that championing causes such as pediatric healthcare innovation not only aligns with Georgia Tech’s mission, but also with the vision surrounding the new infrastructure being built across campus.

“We're committed to turning our city and our neighborhood into a hub of innovation, and the area of life sciences is one of those areas that we are supporting — including our new Science Square neighborhood, which is devoted to precisely this,” he said.

Though industry events happen every year, what makes PHIS unique is its goal of uniting not only clinicians and healthcare administrators, but also researchers, investors, and entrepreneurs.  Attendees are united around a shared goal of solving systemic problems and, ultimately, saving and improving the lives of children. Julia Kubanek, Georgia Tech’s Vice President for Interdisciplinary Research, said that this collaborative approach provides a unique opportunity to progress ideas and technologies that impact the industry.

“Particularly in the pediatric space, the market is relatively small. When you have a specialized pediatric technology, it's sometimes difficult to get the resources to advance that into clinical trials and into products that can go to market,” she said. “This environment that the summit creates is a supportive one for solving those problems and advancing life-saving research.”

While this was the third year that the event featured a pitch competition, it was the first year that winners were awarded monetary prizes. By bringing startups and investors together, the PHIS plays a vital role in getting impactful research from conceptual to consumer ready. This year’s winners included: Luminoah in first place, Rhaeos in second, and AcQumen Medical in third.

Though the event does encourage friendly competition, the ultimate goal remains to improve the lives of children and their families through collaboration, thought leadership, and innovation.

“Our north star is taking care of children,” Anthony Chang, founder of ISPI, said in his opening remarks. “I think we underestimate how much we learn together. I look at our jobs not as jobs but as a special calling — taking care of children.”

In addition to PIN, ISPI, and PDC, the event was sponsored by Georgia Tech’s Office of Corporate Engagement, Shriner’s Children’s Research Institute, Children’s Healthcare of Atlanta, the Georgia Department of Economic Development, the Georgia Research Alliance, and the International Children’s Advisory Network, among others.

Despite the nursery rhyme about three blind mice, mouse eyesight is surprisingly sensitive. Studying how mice see has helped researchers discover unprecedented details about how individual brain cells communicate and work together to create a mental picture of the visual world.

I am a neuroscientist who studies how brain cells drive visual perception and how these processes can fail in conditions such as autism. My lab “listens” to the electrical activity of neurons in the outermost part of the brain called the cerebral cortex, a large portion of which processes visual information. Injuries to the visual cortex can lead to blindness and other visual deficits, even when the eyes themselves are unhurt.

Understanding the activity of individual neurons – and how they work together while the brain is actively using and processing information – is a long-standing goal of neuroscience. Researchers have moved much closer to achieving this goal thanks to new technologies aimed at the mouse visual system. And these findings will help scientists better see how the visual systems of people work.

The Mind in the Blink of an Eye

Researchers long thought that vision in mice appeared sluggish with low clarity. But it turns out visual cortex neurons in mice – just like those in humans, monkeys, cats and ferrets – require specific visual features to trigger activity and are particularly selective in alert and awake conditions.

My colleagues and I and others have found that mice are especially sensitive to visual stimuli directly in front of them. This is surprising, because mouse eyes face outward rather than forward. Forward-facing eyes, like those of cats and primates, naturally have a larger area of focus straight ahead compared to outward-facing eyes.

This finding suggests that the specialization of the visual system to highlight the frontal visual field appears to be shared between mice and humans. For mice, a visual focus on what’s straight ahead may help them be more responsive to shadows or edges in front of them, helping them avoid looming predators or better hunt and capture insects for food.

Importantly, the center of view is most affected in aging and many visual diseases in people. Since mice also rely heavily on this part of the visual field, they may be particularly useful models to study and treat visual impairment.

A Thousand Voices Drive Complicated Choices

Advances in technology have greatly accelerated scientific understanding of vision and the brain. Researchers can now routinely record the activity of thousands of neurons at the same time and pair this data with real-time video of a mouse’s face, pupil and body movements. This method can show how behavior interacts with brain activity.

It’s like spending years listening to a grainy recording of a symphony with one featured soloist, but now you have a pristine recording where you can hear every single musician with a note-by-note readout of every single finger movement.

Using these improved methods, researchers like me are studying how specific types of neurons work together during complex visual behaviors. This involves analyzing how factors such as movement, alertness and the environment influence visual activity in the brain.

For example, my lab and I found that the speed of visual signaling is highly sensitive to what actions are possible in the physical environment. If a mouse rests on a disc that permits running, visual signals travel to the cortex faster than if the mouse views the same images while resting in a stationary tube – even when the mouse is totally still in both conditions.

In order to connect electrical activity to visual perception, researchers also have to ask a mouse what it thinks it sees. How have we done this?

The last decade has seen researchers debunking long-standing myths about mouse learning and behavior. Like other rodents, mice are also surprisingly clever and can learn how to “tell” researchers about the visual events they perceive through their behavior.

For example, mice can learn to release a lever to indicate they have detected that a pattern has brightened or tilted. They can rotate a Lego wheel left or right to move a visual stimulus to the center of a screen like a video game, and they can stop running on a wheel and lick a water spout when they detect the visual scene has suddenly changed.

Mice can also use visual cues to focus their visual processing to specific parts of the visual field. As a result, they can more quickly and accurately respond to visual stimuli that appear in those regions. For example, my team and I found that a faint visual image in the peripheral visual field is difficult for mice to detect. But once they do notice it – and tell us by licking a water spout – their subsequent responses are faster and more accurate.

These improvements come at a cost: If the image unexpectedly appears in a different location, the mice are slower and less likely to respond to it. These findings resemble those found in studies on spatial attention in people.

My lab has also found that particular types of inhibitory neurons – brain cells that prevent activity from spreading – strongly control the strength of visual signals. When we activated certain inhibitory neurons in the visual cortex of mice, we could effectively “erase” their perception of an image.

These kinds of experiments are also revealing that the boundaries between perception and action in the brain are much less separate than once thought. This means that visual neurons will respond differently to the same image in ways that depend on behavioral circumstances – for example, visual responses differ if the image will be successfully detected, if it appears while the mouse is moving, or if it appears when the mouse is thirsty or hydrated.

Understanding how different factors shape how cortical neurons rapidly respond to visual images will require advances in computational tools that can separate the contribution of these behavioral signals from the visual ones. Researchers also need technologies that can isolate how specific types of brain cells carry and communicate these signals.

Data Clouds Encircling the Globe

This surge of research on the mouse visual system has led to a significant increase in the amount of data that scientists can not only gather in a single experiment but also publicly share among each other.

Major national and international research centers focused on unraveling the circuitry of the mouse visual system have been leading the charge in ushering in new optical, electrical and biological tools to measure large numbers of visual neurons in action. Moreover, they make all the data publicly available, inspiring similar efforts around the globe. This collaboration accelerates the ability of researchers to analyze data, replicate findings and make new discoveries.

Technological advances in data collection and sharing can make the culture of scientific discovery more efficient and transparent – a major data informatics goal of neuroscience in the years ahead.

If the past 10 years are anything to go by, I believe such discoveries are just the tip of the iceberg, and the mighty and not-so-blind mouse will play a leading role in the continuing quest to understand the mysteries of the human brain.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

“It has been a pleasure for the Center for Programs to Increase Engagement in the Sciences (C-PIES) to collaborate with Google and the College of Sciences Advisory Board to bring this fellowship, which will positively impact our community and highlight how science can align with public good,” says Lewis A. Wheaton, professor in the School of Biological Sciences and director of C-PIES. 

In the year ahead, the fellows will work with C-PIES and community partners on campus and in the metro Atlanta area to develop projects in one of three priority areas: civic and policy engagement, community-engaged research, and K-12 research outreach. 

The fellowship was open to all graduate students in the College of Sciences, and four inaugural fellows — Aniruddh Bakshi, Katherine Slenker, Miriam Simma, and Nikolai Simonov — were named based on their exciting, yet feasible applications.

Fellow Aniruddh Bakshi: Strengthening trust in science 

Ph.D. student Aniruddh Bakshi studies the problem of drug delivery at the intersections of organic chemistry, biochemistry, and immunology. As mRNA vaccines are closely related to his area of research, he sees the need for a grassroots outreach movement from young academics to help bolster public confidence in rigorous scientific methodology. 

In collaboration with local hospitals and nonprofits, his proposed project is to start a social media content series, titled “A Day in the Life of a Ph.D. Student,” to show the realities of graduate school for those interested in this career path while connecting his research to broader public issues. 

“Science has the power to solve urgent problems, but only if people understand and trust it,” says Bakshi. “Through this fellowship, I will use my research and outreach efforts to help strengthen that trust — showing how discoveries in drug delivery and vaccine design can make a real difference in people’s lives.” 

Fellow Katherine Slenker: Creating a biodiversity data network 

Atlanta is often referred to as “the city in a forest,” but according to Ph.D. student Katherine Slenker, wildlife has a difficult time navigating across roads and housing developments, often resulting in human-wildlife conflict. 

“Conservation ecologists have long recommended that the movement of wildlife could be eased through the creation of ‘ecological corridors,’ which connect greenspaces and wildlife populations,” she explains. “Determining the movement patterns of wildlife, and where such corridors may be best situated, requires that we first understand what species reside in the metro Atlanta area as well as how they are expected to disperse.”

As a fellow, Slenker plans to build a biodiversity data network by comparing wildlife monitoring at Davidson-Arabia Mountain Nature Preserve and Stone Mountain Park and increasing the coalition of metro Atlanta researchers. This data can be used in the development of ecological corridors to reduce clashing between humans and wildlife, notably animals struck by vehicles, and improve ecosystem health at these parks. 

Fellow Miriam Simma: Making structural biology research more accessible 

The study of crystallography is vital in academia, industry, and medicine because it enables researchers to decipher the atomic structures of proteins, but it is scarcely taught outside of graduate school. Ph.D. student Miriam Simma wants to change that. 

Her proposed project is to introduce protein crystallography to K-12 students and teachers through hands-on activities in local high school classrooms and to the public during the Atlanta Science Festival at Georgia Tech.

“My vision is to make structural biology research accessible, so everyone can engage with cutting-edge scientific research — fostering curiosity and interest in STEM careers,” says Simma. “Long term, I will synthesize these activities into a chemical education article that introduces K-12 students to protein structure and function.” 

Fellow Nikolai Simonov: Mentoring middle school scientists 

Last year, Ph.D. student Nikolai Simonov became involved in the GoSTEM Club at Lilburn Middle School — leading student activities and recruiting other graduate student volunteers. In partnership with Georgia Tech’s Center for Education Integrating Science, Mathematics and Computing, the club is a weekly afterschool program for students, many of whom come from underserved backgrounds, to grow their scientific curiosity. 

“I assembled a team of 10 Tech graduate students who could explain complex scientific concepts in approachable ways for middle school students. Through this fellowship, we are excited to enrich the GoSTEM Club with an ongoing mentorship program and materials for more ambitious science fair projects,” shares Simonov. 

As part of the program, club members can meet one-on-one with Georgia Tech mentors to discuss their educational and career goals. “By sharing their stories and connecting scientific ideas to real-world applications, our mentors aim to show students that STEM is not only accessible but a path toward a fulfilling life,” he adds.

Despite their importance, most of what scientists know about proteins only comes from a small sample size. This stands in the way of fully understanding how most proteins work and unlocking their full potential.

Georgia Tech’s Yunan Luo believes artificial intelligence (AI) could fill this knowledge gap. The National Science Foundation agrees. Luo is the recipient of an NSF Faculty Early Career Development (CAREER) award. 

“So much of biology depends on knowing what proteins do, but decades of research have concentrated on a relatively small set of well-studied proteins. This imbalance in scientific attention leads to a distorted view of the biological landscape that quietly shapes our data and our algorithms,” Luo said.

“My group’s goal is to build machine learning (ML) models that actively close this gap by generating trustworthy function predictions for the many proteins that remain understudied.”

[Related: Yunan Luo to use AI for Protein Design and Discovery with Support of $1.8 Million NIH Grant]

In his proposal to NSF, Luo coined this rich-get-richer effect “annotation inequality.” 

One problem of annotation inequality is that it slows progress in disease prognosis, drug discovery, and other critical biomedical areas. It is challenging to innovate the few proteins that scientists already know so much about. 

A cascading effect of annotation inequality is that it diminishes the effectiveness of studying proteins with AI.  

AI methods learn from existing experimental data. Datasets skewed toward well-known proteins propagate and become entrenched in models. Over time, this makes it harder for computers to research understudied proteins. 

“Protein annotation inequality creates an effect analogous to a vast library where 95% of patrons only read the top 5% popular books, leaving the rest of the collection to gather dust,” Luo said.

“This has resulted in knowledge disparities across proteins in current literature and databases, biasing our understanding of protein functions.”

The NSF CAREER award will fund Luo with over $770,000 for the next five years to tackle head-on the problem of protein annotation inequality.

Luo will use the grant to build an accurate, unbiased protein function prediction framework at scale. His project aims to:

• Reveal how annotation inequality affects protein function prediction systems
• Create ML techniques suited for biological data, which is often noisy, incomplete, and imbalanced  
• Integrate data and ML models into a scalable framework to accelerate discoveries involving understudied proteins

More enduring than the ML framework, Luo will leverage the NSF award to support educational and outreach programs. His goal is to groom the next generation of researchers to study other challenges in computational biology, not just the annotation inequality problem.

Luo teaches graduate and undergraduate courses focused on computational biology and ML. Problems and methods developed through the CAREER project can be used as course material in his classes.

Luo also championed collaboration with Georgia Tech’s Center for Education Integrating Science, Mathematics, and Computing (CEISMC) in his proposal. 

Through this partnership, local high school teachers and students would gain access to his data and models. This promotes deeper learning of biology and data science through hands-on experience with real-world tools.  

Luo sees reaching students and the community as a way of paying forward the support he received from Georgia Tech colleagues. 

“I am incredibly grateful for this recognition from the NSF,” said Luo, an assistant professor in the School of Computational Science and Engineering (CSE). 

“This would not have been possible without my students and collaborators, whose hard work laid the groundwork for this proposal.”

Luo praised CSE faculty members B. Aditya Prakash, Xiuwei Zhang, and Chao Zhang for their guidance. All three study machine learning and computational bioscience, two of CSE’s five core research areas. 

Luo also thanked Haesun Park for her support and recommendation for the CAREER award. Park is a Regents’ Professor and the chair of the School of CSE.

Though decorated with awards and appearances in leading journals, Zhang will achieve his greatest accomplishment tonight at McCamish Pavilion. He will join the Class of 2025 in walking across the stage, receiving diplomas, and graduating from Georgia Tech.

Before he “gets out” of Georgia Tech, we interviewed Zhang to learn more about his Ph.D. journey and where his degree will take him next. 

Graduate: Ziqi Zhang

Research Interests: Machine learning, foundational models, cellular mechanisms, single-cell gene sequencing, gene regulatory networks

Education: Ph.D. in Computational Science and Engineering

Faculty Advisor: School of CSE J.Z. Liang Early-Career Associate Professor Xiuwei Zhang

What persuaded you to study at Georgia Tech? 

I chose Georgia Tech because it is one of the top engineering institutions in the United States, known for its strength in machine learning and data science. The university offers exceptional research resources and the opportunity to work with leading scholars in my field. Georgia Tech also has very good research infrastructure. The Coda Building is one of the most well-designed and productive research environments I have experienced. Having access to such a space has been a genuine privilege.

How has working on your CSE degree helped you so far in your career?

Working toward my CSE degree has been instrumental in my career development. As an interdisciplinary program, CSE has equipped me with strong computational skills while also deepening my understanding of key application domains. This breadth of training has opened more opportunities during my job and internship searches. In addition, CSE community events, such as HotCSE, the weekly coffee hour, and faculty recruiting activities, have helped me strengthen my scientific communication skills, which are essential for my long-term career growth.

What research project from Georgia Tech are you most proud of?

My favorite research project was scMoMaT, a matrix tri-factorization algorithm for single-cell data integration. I invested a significant amount of time and effort into this work, iterating on the model many times. I’m very proud that it ultimately evolved into a clean, robust, and elegant algorithm.

What advice would you give someone interested in graduate school?

It is important to find an advisor who is supportive and genuinely invested in your career development. A Ph.D. is not an easy journey, and you will inevitably encounter challenges along the way. Having an advisor who can provide thoughtful guidance and dedicated mentorship is one of the most crucial factors in helping you navigate those difficulties.

What is your most favorite memory from Georgia Tech?

CSE’s new student campus visit day every year was one of my favorite times of the year. It was always fun to meet new people, have good food, and enjoy the beautiful view from the Coda rooftop.

What are your plans after graduation?

I plan to keep working in academia after graduation. I’m on the job hunt, currently applying for positions and preparing for interviews.

The award — named in recognition of Carl Gans’ contributions to animal morphology, biomechanics, and functional biology — is one of the highest honors from the Society for Integrative and Comparative Biology (SICB), and recognizes Manafzadeh’s “exceptional creativity and originality in comparative biomechanics research as well as her strong mentoring contributions.”

“I’m very fortunate to have done science with incredible mentors, collaborators, and students who’ve helped me develop this body of research,” she says. “I’m grateful to be recognized with the Carl Gans Award, and look forward to continuing to explore new ways to study biomechanics when I start my lab at Georgia Tech.”

The new Manafzadeh Lab at Georgia Tech will investigate how joints work and where they come from — both evolutionarily and developmentally. With powerful new technology, called X-Ray Reconstruction of Moving Morphology (XROMM), Manafzadeh can look inside bodies with 4D “X-ray vision” — and can create animations of moving skeletons with sub-millimeter precision. 

“This research has the potential to transform our understanding of animal motion,” she says, “and that can ultimately open doors to everything from personalized surgical treatments for people to new designs for bio-inspired robots.”

As part of the award, Manafzadeh will deliver a plenary speech on “Joints: Form, Function, and the Future of Comparative Biomechanics” this January at the annual SICB meeting in Portland, Oregon.

Imagine stepping into a space the size of multiple football fields — only instead of turf and goalposts, it’s filled with science. Every inch is alive with posters, equipment demos, and researchers sharing the latest breakthroughs.  

Lung-on-a-chip platforms provide researchers a window into organ behavior. They are about the size of a postage stamp, etched with tiny channels and lined with living human cells. Roy and Singh’s innovation was adding a working immune system — the missing piece that turns a chip into a true model of how the lung fights disease.

Now, researchers can watch how lungs respond to threats, how inflammation spreads, and how healing begins.
 

The Human Stakes

For millions of people struggling with lung disease, everyday life can feel nearly impossible, whether it’s climbing stairs, carrying groceries, or even laughing too hard. Doctors and scientists have attempted for decades to unlock what really happens inside fragile lungs.

"This unique lung-on-a-chip model opens new, preclinical pathways of discovery that will allow researchers to better understand the interplay of immune responses to severe viral infections and evaluate critical antiviral treatments,” said Roy.

For Singh, the Carl Ring Family Professor in the George W. Woodruff School of Mechanical Engineering with a joint appointment in the Wallace H. Coulter Department of Biomedical Engineering, this research is deeply personal. He lost an uncle when an infection overwhelmed his cancer-weakened immune system.

“That experience stays with you,” Singh reflected. “It made me want to build systems that could predict and prevent outcomes like that, so fewer families go through what mine did. I think about my uncle all the time. If work like this means fewer families lose someone they love, then it’s worth everything.”

That motivation pushed his team to reimagine what a lung-on-a-chip could do, setting the stage for the breakthroughs that followed.
 

When the Lung Fought Back

The turning point came when Roy’s and Singh’s team peered through a microscope and saw something no one had ever witnessed on a chip: blood and immune cells coursing through tiny vessel-like structures, behaving just as they do in a living lung.

For years, researchers had struggled to add immunity to organ-on-a-chip systems. Immune cells often died quickly or failed to circulate and interact with tissue the way they do in people. the team solved that problem, creating a chip where immune cells could survive and coordinate a defense.

“It was an amazing breakthrough moment,” Singh said.

The true test came when the team introduced a severe influenza virus infection. The lung mounted an immune response that closely mirrored what doctors see in patients. Immune cells rushed to the site of infection, inflammation spread through tissue, and defenses activated in response.

“That was when we realized this wasn’t just a model,” Singh said. “It was capturing the real biology of disease.”

Singh and Roy’s research is published in the journal Nature Biomedical Engineering.
 

A More Human Approach

For decades, lung research has relied on animal models. But mice don’t get asthma like children. Their bodies don’t mount the same defenses.

“Five mice in a cage may respond the same way, but five humans won’t,” Singh explained. “Our chip can reflect that difference. That’s what makes it more accurate, and why it could dramatically reduce the need for animal models.”

Krish Roy emphasized its potential.

“The Food and Drug Administration’s strategic vision on reducing animal testing and developing predictive non-animal models aligns perfectly with our work. This device goes further than ever before in modeling human severe influenza and providing unprecedented insights into the complex lung immune response,” he said.

Fighting More Than the Flu

What began with influenza now expands to a wider range of diseases. Roy and Singh believes the platform can be used to study asthma, cystic fibrosis, lung cancer, and tuberculosis. The researchers are also working to integrate immune organs, showing how the lung coordinates with the body’s defenses.

The long-term vision is personalized medicine: chips built from a patient’s own cells to predict which therapy will work best. Scaling, clinical validation, and regulatory approval will take years, but Singh is undeterred.

“Imagine knowing which treatment will help you before you ever take it,” Singh said. “That’s where we’re headed.”

Where we’re headed, the future doesn’t wait for illness. Instead, it anticipates it, intercepts it, and rewrites the outcome.

Georgia Tech postdoctoral researcher Rachel Ringquist was the first author leading the study.

This research was supported by Wellcome Leap, with additional funding from the National Institutes of Health, Carl Ring Family Endowment, and the Marcus Foundation.

Ringquist, R., Bhatia, E., Chatterjee, P. et al. An immune-competent lung-on-a-chip for modelling the human severe influenza infection response. Nature Biomedical Engineering, September 2025 Vol.9 No.9

DOI: https://doi.org/10.1038/s41551-025-01491-9

“Georgia Tech and UGA's collective commitment to advancing science and technology exceeds the intensity of our athletic rivalry,” Fedorov said. “Together, we’re advancing cell and therapy biomanufacturing to develop lifesaving treatments for the most devastating diseases.”
 
Georgia Tech’s Francisco Robles and UGA’s Lohitash Karumbaiah are using manufactured T cells to target cancer. Robles, who leads the Optical Imaging and Spectroscopy Lab in the Wallace H. Coulter Department of Biomedical Engineering, developed quantitative Oblique Back-illumination Microscopy (qOBM) to monitor tumor growth in real time. The method allows scientists to visualize patient-derived glioblastoma cell clusters generated in the Karumbaiah Lab, tracking tumor structure and behavior at various stages.

“Assessing therapeutic potency is often complex, costly, and ineffective for solid tumors,” Karumbaiah said. “qOBM simplifies the process by providing real-time, label-free monitoring of therapeutic efficacy against 3D solid tumors.”   

The work could help doctors personalize cancer treatments by providing early, detailed signs of whether a therapy is working.

“This technique is more compact and affordable and lets us watch T cells attack cell cultures in real time,” Robles said. “This breakthrough could transform how we study disease and screen new treatments.”

A Playbook for Local Healthcare
Created in 2007 by the National Institutes of Health, Georgia CTSA is one of several NIH-funded national partnerships advancing new health therapeutics and practices. Since 2017, it has comprised UGA, Georgia Tech, Emory, and the Morehouse School of Medicine. The alliance’s reach extends far beyond campus borders, bringing together researchers, clinicians, professional societies, and community and industry partners to identify local health challenges and translate research into practical solutions.

And out of this alliance have come many collaborative studies among CTSA’s members.

One, the Georgia Health Landscape Dashboard, is a tool to identify local health gaps and connect regional health professionals or policymakers with the researchers who can best address their community’s challenges. UGA College of Family and Consumer Sciences Associate Professors Alison Berg and Dee Warmath, along with community health engagement coordinator Courtney Still Brown, are working with Georgia Tech’s Jon Duke, director of the Center for Health Analytics and Informatics at the Georgia Tech Research Institute and a principal research scientist in the School of Interactive Computing.

The dashboard has already helped match researchers with communities by combining epidemiological data with “community voice” insights through surveys of residents and local leaders.

For example, when examining diabetes data, the dashboard indicates Randolph County has the state’s highest prevalence, despite declining by about 8% between 2021-24. Meanwhile, Treutlen County’s rate increased 29.2% during the same period. Perhaps Treutlen’s need for diabetic care is a growing concern, while Randolph’s is being addressed. And perhaps Hancock County, which ranks diabetes its top priority in the community voice category, is in search of immediate solutions.

“The Landscape Dashboard is a fantastic example of how the unique expertise found at Georgia Tech and UGA can be brought together to create something truly valuable for all Georgia,” Duke said. “By bringing together a range of data sources and health analytics approaches, this collaboration has created a tool that delivers novel insights into health, community, and policy across the state.”

Supported by UGA Cooperative Extension and the Biomedical and Translational Sciences Institute, the project leverages a network of agents in every county across the state. Warmath said the project’s strength lies in its ability to connect research with real-world needs.

“To build a community-responsive ecosystem for biomedical research, scientists must recognize local needs, share progress with communities to foster trust and acceptance, recruit clinicians and industry partners, and strengthen the relationships between patient and caregiver,” Warmath said.

Teaming Up for Maternal Health
Warmath and a team of researchers at UGA, Georgia Tech, and Emory are also collaborating on an NIH-funded project uniting experts in maternal health, biostatistics, and consumer science to explore how wearable technologies could improve delivery-room care.

During childbirth, clinicians monitor countless maternal and fetal vitals — contractions, heart rates, oxygen levels, kidney function, and more. What new insights, the researchers asked, could advanced wearable technologies offer in the delivery room, and what barriers might prevent their use?

Using nationwide surveys and focus groups, the team gathered information from a representative sample of pregnant, postpartum, and reproductive-age women, as well as healthcare professionals, to examine acceptance of wearable health technologies during labor and delivery. In their analysis of this rich data source, the team is identifying key variables that reveal gaps in technology acceptance and the unique needs of diverse maternal populations.

Each partner institution brings unique expertise. At Emory, principal investigator Suchitra Chandrasekaran contributes clinical insights from direct patient care. At UGA, Warmath applies her knowledge in consumer science to analyze end-user motivation, attitudes, and behaviors. At Georgia Tech, experts like Sarah Farmer in the Center for Advanced Communications Policy’s Home Lab facilitate large-scale data collection.

With data collection now complete, the team is analyzing results to inform future design and deployment of wearable technologies.
“Each school has a different perspective,” Farmer said. “It’s not as simple as one school does this but doesn’t do that. Each has their expertise, but they offer different perspectives and different resources that, when pooled, can make our research that much more effective.”

Whether advancing maternal health, mapping Georgia’s health needs, or engineering next-generation therapies, UGA and Georgia Tech continue to prove that collaboration is Georgia’s strongest tradition. Further, the undergraduate and graduate students who work in these labs and others represent the state’s highly skilled workforce of tomorrow.

“When our institutions work together, Georgia wins,” Warmath said.

— By David Mitchell

Tech College of Engineering alumni Chad Pozarycki, Ph.D., CHBE, 2022, and José Andrade, AE, 2025, are on a mission to make biochemical monitoring more accessible — with a focus on preventing disease. Today, their startup Deleon, using NASA’s technology (originally designed to search for life on Mars) and metabolomics, provides a system that uses daily urine sampling to track metabolites related to overtraining, stress, and recovery. Future applications will be aimed at early disease detection.

“Something that frustrated me about metabolomics was its lack of focus on preventive care,” said Andrade. “We created Deleon by combining these ideas and tracking the human metabolome to optimize for healthy lifestyles.”

The Deleon founders began the company shortly after Pozarycki completed his graduate studies at Georgia Tech, with Andrade moonlighting and Pozarycki working a part-time job at Georgia Tech’s bike shop to keep the project afloat. In the beginning, funding was a major challenge. 

“I finished my Ph.D., was working on Deleon, and didn’t have any income. CREATE-X gave us $5,000 in funding, which motivated us to keep going on this project,” said Pozarycki.

CREATE-X, Georgia Tech’s campus-wide initiative to instill entrepreneurial confidence and help students launch startups, provided more than funding. Through the program, Deleon received guidance on finding potential customers. 

“The one-on-one advice from expert CREATE-X entrepreneurs and organizers like Rahul [CREATE-X director] and Margaret [LAUNCH associate director] was super valuable and helped us focus on launching our minimum viable product and getting our first customers,” said Andrade.

The program’s culminating event, Demo Day, gave Deleon a platform to present to investors and the public. Among dozens of student-led startups, Deleon’s data-driven approach attracted strong interest. The exposure led to an eventual $850,000 investment, partially funded by Georgia Tech's early-stage fund, GTF Ventures. This investment allowed the founders to work full-time on the company, hire a team, and build a lab space.

“I would recommend the CREATE-X program to anyone,” Pozarycki said. “Even if you don’t think you want to start a company, there’s a lot you can learn about commercialization in this program that may change your mind and give you more control over your own fate.”

Deleon’s path from concept to launch highlights the growing role of Georgia Tech’s entrepreneurial ecosystem in supporting student innovation. Programs like CREATE-X not only help students build companies but also contribute to regional economic growth by keeping talent and investment in the Southeast.

“CREATE-X is the best environment on campus to learn by doing,” Pozarycki said. “You are encouraged to build something real, not just talk about it. You’ll leave knowing how to talk to customers, how to pitch, and how to think like a founder.”

Opportunities for Entrepreneurs

Students, faculty, researchers, and alumni interested in developing their own startups are encouraged to apply to CREATE-X’s Startup Launch. The early admission deadline to apply for Startup Launch is Nov. 17. Spots are limited. Apply now for a higher chance of acceptance and early feedback.

The event marks the culmination of the semester-long I2P course, where undergraduate students develop functional prototypes aimed at solving real-world problems. Prototypes this semester include a smart military drone, a gentler device for cervical cancer screening, a rotating espresso station, tools to keep AI safe, compact data centers, systems that simulate cyberattacks to help companies strengthen their defenses, and many more. 

The showcase is free and open to students, faculty, staff, and members of the local community. 

Winning teams will receive prizes and a “golden ticket” into CREATE-X’s Startup Launch, a summer accelerator that provides optional seed funding, accounting and legal service credits, mentorship, and more to help students turn their prototypes into viable startups.

This is a free event, and refreshments will be provided. Register for the Fall 2025 I2P Showcase today!

As Schmidt Polymaths, the researchers pursue new approaches compared to previous work. The new cohort of polymaths will answer questions like how to expand access to healthcare with low-cost technologies, what happens to our chromosomes when we age and how to create more accurate computer simulations of climate. 

Bhamla, associate professor in ChBE@GT, is the first Schmidt Polymath from Georgia Tech. He will develop low-cost technologies to tackle planetary-scale challenges, including AI-enabled point-of-care diagnostics in low-resource environments, and he will also engineer autonomous morphing machines that adapt, evolve and learn like living systems.

The eight selected scientists represent the fifth cohort of the highly selective Schmidt Polymaths program. Awardees must have been tenured—or achieved similar status—within the previous three years. Previous cohorts have used the award to design new sensor devices, perform experiments at atomic resolutions, analyze trees of life with faster and more efficient algorithms, discover new mathematical formulas assisted by AI, and more. 

Drawn from universities worldwide and selected through a competitive application process, Schmidt Polymaths are required to demonstrate past ability and future potential to pursue early-stage, novel research that would otherwise be challenging to fund—even without the current dramatic declines in U.S. funding for science. 

“Our world is one deeply interconnected system---but to study it more deeply, we’ve divided it into increasingly narrow categories,” said Wendy Schmidt, who co-founded Schmidt Sciences with her husband Eric. “Schmidt Polymaths see the bigger picture, pursue answers beyond boundaries and expand the edges of what’s possible.  Their work can help steer  us all toward a healthier  future, for people and the planet.”

About Schmidt Sciences

Schmidt Sciences is a nonprofit organization founded in 2024 by Eric and Wendy Schmidt that works to accelerate scientific knowledge and breakthroughs with the most promising, advanced tools to support a thriving planet. The organization prioritizes research in areas poised for impact including AI and advanced computing, astrophysics, biosciences, climate, and space—as well as supporting researchers in a variety of disciplines through its science systems program.

RELATED: Forbes featured Bhamla in the article: Saad Bhamla Is A Polymath

Understanding the brain is key to unlocking human health and flourishing. The need has never been more urgent, but this challenge is too vast for any single discipline to solve alone.

That’s why Georgia Tech recently launched the Institute for Neuroscience, Neurotechnology, and Society (INNS). A step toward a more connected, collaborative future, INNS brings together experts from across Georgia Tech’s seven colleges and the Georgia Tech Research Institute (GTRI) to study the brain in ways that connect scientific discovery with technological innovation and real-world societal needs.

INNS supports research that crosses traditional academic boundaries. As an Interdisciplinary Research Institute (IRI), it builds community, fosters collaboration, and fills critical gaps in education, professional development, and research infrastructure.

“Georgia Tech has a long-standing culture of interdisciplinary collaboration — it’s in our DNA,” says INNS Executive Director Chris Rozell. Rozell also serves as Julian T. Hightower Chaired Professor in the School of Electrical and Computer Engineering. “INNS builds on that strength to create a space where breakthroughs in neuroscience and neurotechnology can move from lab to life, impacting real people in real ways.”

A Community Built to Collaborate

INNS is home to a growing network of faculty, students, and research centers spanning the full spectrum of Georgia Tech’s research expertise. This diversity is not just a feature, it’s the foundation.

That foundation was laid over decades of growth, vision, and grassroots momentum. Georgia Tech welcomed its first neuroscience-focused faculty member in 1990, sparking a steady expansion of brain-related research across campus. As more faculty joined and new focus areas emerged, a vibrant, cross-disciplinary community began to take shape.

In 2014, that community organized under the name GT Neuro, a grassroots initiative that united researchers who shared a passion for understanding the brain. This collective energy led to new educational programs, including the launch of Georgia Tech’s undergraduate neuroscience major in the College of Sciences.

“Our undergraduate students absolutely love teaching others about Neuroscience,” said Christina Ragan, director of Outreach for the Undergraduate Neuroscience Program and senior academic professional in the School of Biological Sciences. “I'm really excited to explore ways for INNS to connect our neuroscience community at Tech with the public.”

By 2023, the Neuro Next Initiative launched to bring together leaders from across campus and chart a strategic path forward — the result of nearly two years of community-driven planning to formalize and expand Georgia Tech’s neuroscience ecosystem. 

“The launch of INNS has built on the momentum of the Neuro Next Initiative, which ignited crucial conversations and fostered new collaborations between researchers at GTRI and Georgia Tech faculty,” says Tabitha Rosenbalm, GTRI senior research engineer. “The remarkable demonstration at Interface Neuro — witnessing a quadriplegic man walk and communicate thanks to innovative research — underscores the transformative breakthroughs possible when academic and applied researchers unite. INNS is uniquely positioned to serve as a catalyst, propelling Atlanta, Georgia Tech, and GTRI as national leaders in neurotechnology, driving advancements in both human health and engineering innovation.”

INNS is also helping shape the future of education. A new interdisciplinary Ph.D. program in neuroscience and neurotechnology welcomed its first cohort this fall, and INNS is poised to support it with professional development, research opportunities, and community engagement.

Breaking Boundaries to Advance Brain Science

Whether it’s developing neurotechnologies, designing therapeutic environments, or exploring the ethical implications of brain research, INNS is here to support work that spans fields and impacts lives.

“To responsibly address the societal and human impacts of advances in neuroscience and neurotechnology, we first need to understand them,” said Margaret Kosal, professor and director of Graduate Students in the Ivan Allen College of Liberal Arts. “That requires real and substantive collaboration beyond traditional engineering or biology labs.”

One example of INNS in action is the Smart Transitional Home Lab, a project funded by the inaugural INNS/Shepherd Center Seed Grant. This initiative brings together experts in architecture, inclusive design, neuroengineering, and rehabilitation to prototype environments that actively support stroke recovery, blending rigorous research with human-centered design.

“The establishment of INNS creates a powerful platform where diverse minds, from neuroscience to architecture to rehabilitation, can converge around a shared mission to advance human health,” says Hui Cai, professor in the School of Architecture, executive director of the SimTigrate Design Center, and co-leader of the project. “It enables interdisciplinary work with the potential to transform lives and redefine how we design for healing and recovery.”

“From whole brain recordings, to mapping the connectome, to the incredible advances in artificial intelligence, it's never been a more exciting time to study the mind and brain,” says Bob Wilson, director of the Center of Excellence for Computation and Cognition and associate professor in the School of Psychology. “I'm extremely excited for INNS to act as a central hub, building the neuroscience community at Georgia Tech and beyond.”

Join Us

INNS is more than an institute, it’s a growing, vibrant community of researchers, educators, students, and partners. Together, we’re working to understand the brain, develop technologies that improve lives, and ensure those innovations serve society responsibly.

Whether you're a student, researcher, policymaker, or simply curious about the brain, INNS is your gateway to interdisciplinary neuroscience at Georgia Tech. Get involved at neuro.gatech.edu.

Nathan Wallace was born with proximal femoral focal deficiency, a congenital limb disorder, which led to the amputation of his left foot at 8 months old. He was fitted for his first prosthetic at 13 months.  

A team of Georgia Tech researchers wanted to ease that struggle, and robotic exoskeletons offered a promising path. Their findings point to a simple but powerful shift: exoskeletons that adapt to people, rather than forcing people to adapt to the machine. Using artificial intelligence (AI) to learn the rhythm of patients’ strides in real time, the team showed how these devices can reduce strain and increase efficiency. They also demonstrated how the technology can help restore confidence for stroke survivors. 

The Robot Finds the Rhythm

A robotic exoskeleton is a wearable device that helps people move with mechanical support. Traditional exoskeletons require endless manual adjustments — turning knobs, calibrating settings, and tweaking controls. 

“It can be frustrating, even nearly impossible, to get it right for each person,” said Aaron Young, associate professor in the George W. Woodruff School of Mechanical Engineering. “With AI, the exoskeleton figures out the mapping itself. It learns the timing of someone’s gait through a neural network, without an engineer needing to hand-tune everything.”

The software monitors each step, instantly updates, and fine-tunes the support it provides. Over time, the exoskeleton aligns its movements with the unique gait of the person wearing it. In this study, the research team used a hip exoskeleton, which provides torque at the hip joint — in other words, adding power to help stroke survivors walk or move their legs more easily.
 

Taking Smarter Steps

Walking after a stroke can be tough and unpredictable. A patient’s stride can change from one day to the next, and even from one step to the next. Most exoskeletons aren’t built for that kind of variation. They are designed around the steady, even gait of healthy young adults, which can leave stroke survivors feeling more unsteady than supported.

Young’s breakthrough, detailed in IEEE Transactions on Robotics, is a neural network — a type of AI that learns patterns much like the human brain does. Sensors at the hip pick up how someone is moving, and the network translates those signals into just the right boost of power to support each step. It quickly figures out a person’s unique walking pattern. But lead clinician Kinsey Herrin said the AI’s learning doesn’t stop there. It keeps adjusting as the patient walks, so the exoskeleton can stay in sync even during stride shifts.

“The speed really surprised us,” Young said. “In just one to two minutes of walking, the system had already learned a person’s gait pattern with high accuracy. That’s a big deal, to adapt that quickly and then keep adapting as they move.”

Tests showed the system was far more accurate than the standard exoskeleton. It reduced errors in tracking stroke patients’ walking patterns by 70%.

Young emphasized that this research is about more than metrics. “When you see someone able to walk farther without becoming exhausted, that’s when you realize this isn’t just about robotics — it’s about giving people back a measure of independence,” he said.
 

Adapting Anywhere

Every exoskeleton comes with its own set of sensors, so the data they collect can look completely different from one device to the next. A neural network trained on one machine often stumbles when it’s moved to another. To get around that, Young’s team designed software that works like a universal adapter plug — no matter what device it’s connected to, it converts the signals into a form the AI can use. After just 10 strides of calibration, the system cut error rates by more than 75%.

“The goal is that someone could strap on a device, and, within a minute, it feels like it was built just for them,” Young said.


A Step Toward the Future

While the study centered on stroke survivors, the implications are far broader. The same adaptive approach could support older adults coping with age-related muscle weakness, people with conditions like Parkinson’s or osteoarthritis, or even children with neurological disabilities. 
Young and his team are now running clinical trials to measure how well the AI-powered exoskeleton supports people in a wide range of everyday activities.

“There’s no such thing as an ‘average’ user,” Young said. “The real challenge is designing technology that can adapt to the full spectrum of human mobility.”

If Georgia Tech’s exoskeleton can rise to that challenge, the promise goes well beyond the lab. It could mean a world where technology doesn’t just help people walk — it learns to walk with them.

Inseung Kang, who holds a B.S., M.S., and Ph.D. from Georgia Tech, is the paper’s lead author and now an assistant professor of mechanical engineering at Carnegie Mellon University. He explained that the real promise is in what comes next. 

“We’ve developed a system that can adjust to a person’s walking style in just minutes. But the potential is even greater. Imagine an exoskeleton that keeps learning with you over your lifetime, adjusting as your body and mobility change. Think of it as a robot companion that understands how you walk and gives you the right assistance every step of the way.”

 

Aaron Young is affiliated with Georgia Tech’s Institute for Robotics and Intelligent Machines.

This research was primarily funded by a grant (DP2HD111709-01) from the National Institutes of Health New Innovator Award Program. Georgia Tech researchers have created the first lung-on-a-chip with a functioning immune system, allowing it to respond to infections much like a real human lung. The breakthrough, published in Nature Biomedical Engineering, provides a more accurate way to study diseases, test therapies, and reduce reliance on animal models. With potential applications in conditions from influenza to cancer, the technology opens the door to personalized medicine that predicts how individual patients will respond to treatment.

Purpose Built for AI Discovery

Nexus is Georgia Tech’s next-generation supercomputer, replacing the HIVE. Most operational high-performance computing systems utilized for research were designed before the explosion in Machine Learning and AI. This revolution has already shown successes for scientific research and data analysis in many domains, but the compute power, complex connectivity, and data storage needs for these systems have limited their access to the academic research community. The Nexus supercomputer design process retained a robust HPC system as a base while integrating artificial intelligence, machine learning and large-scale data science analysis from the ground up.

Expert Support for Faculty and Researchers 

The Institute for Data Engineering and Science (IDEaS) and the College of Computing house the Center for Artificial Intelligence in Science and Engineering (ARTISAN) group. This team has collective experience in working with national computational, cloud, commercial and institutional resources for computational activities, and decades of experience in scientific tools that aid in assisting both teaching and research faculty. Nexus is the next logical step, bringing together everything they’ve learned to build a national resource optimized for the future of AI-driven science.

Principal Research Scientist for the ARTISAN team, Suresh Marru, highlighted the need for this new resource, “AI is a core part of the Nexus vision. Today, researchers often spend more time setting up experiments, managing data, or figuring out how to run jobs on remote clusters than doing science. With Nexus, we’re flipping that script. By embedding AI into the platform, we help automate routine tasks, suggest optimal ways to run simulations, and even assist in generating input or analyzing results. This means researchers can move faster from question to insight. Instead of wrestling with infrastructure, they can focus on discovery.”

An Accessible AI Resource for GT & US Scientific Research

90% of Nexus capacity will be made available to the national research community through the NSF Advanced Computing Systems & Services (ACSS) program. Researchers from across the country, at universities, labs, and institutions of all sizes, will have access to this next-generation AI-ready supercomputer. For Georgia Tech research faculty and staff, the new system has multiple benefits:

• 10% of the time on the machine will be available for use by Georgia Tech researchers
• Nexus will allow GT researchers a chance to try out the latest hardware for AI computing
• Thanks to cyberinfrastructure tools from the ARTISAN group, Nexus will be easier to access than previous NSF supercomputers

Interim Executive Director of IDEaS and Regents' Professor David Sherrill notes, "Nexus brings Georgia Tech's leadership in research computing to a whole new level. It will be the first NSF Category I Supercomputer hosted on Georgia Tech's campus. The Nexus hardware and software will boost research in the foundations of AI, and applications of AI in science and engineering."

The Georgia Tech-Shepherd Center Seed Grant Program is part of an ongoing partnership between the two institutions that started in 2023 with the goal of advancing rehabilitative patient care and research.

“The seed grant program is intended to stimulate new interdisciplinary research collaborations by providing seed funding to obtain preliminary data or prototypes necessary for the submission of an external grant or industry opportunities,” says Deborah Backus, vice president of Research and Innovation at Shepherd Center. “As two leading research institutions, we know the potential for advancing rehabilitation therapies is even greater when we work together. We look forward to the solutions, treatments, and therapies that emerge from these initial seed grants.” 

Experts from both institutions evaluated and scored seed grant applications based on the research’s innovation, approach, and potential for training opportunities, as well as its anticipated impact, prospects for commercial translation, and strategy for securing continued funding. This year, each awardee team received close to $50,000.

“We are very excited to launch this new seed grant program, which will spur ideas and propel research forward,” said Michelle LaPlaca, professor in the Coulter Department of Biomedical Engineering and the Georgia Tech lead of the Collaborative. “The complementary expertise of Georgia Tech and Shepherd Center researchers, combined with the motivation to find solutions for individuals with neurological injury and disability, is a winning formula for innovation.”

"Offering new hope for neurorehabilitation patients requires bringing together interdisciplinary researchers to explore new and creative ideas,” adds Chris Rozell, Julian T. Hightower Chaired professor in the School of Electrical and Computer Engineering and the inaugural executive director of the Institute of Neuroscience, Neurotechnology, and Society (INNS) at Georgia Tech. “I'm excited to see the talent at these world class institutions coming together to develop new solutions for these complex problems."

This year’s seed grants were awarded to the following projects:

• Proof of Concept Development of the Recovery Cushion – Stephen Sprigle, professor, School of Industrial Design and School of Mechanical Engineering, Georgia Tech; Jennifer Cowhig, research physical therapist, Shepherd Center.
• Paving a Smooth Path from Hospital to Home: A Feasibility Study of an Integrated Smart Transitional Home Lab to Support Stroke Rehabilitation Patients’ Transition to Home – John Morris, senior clinical research scientist, Shepherd Center; Hui Cai, professor in the School of Architecture, executive director of the SimTigrate Design Center, Georgia Tech.
• A Comparative Analysis of Lower-Limb Exoskeleton Technology for Non-Ambulatory Individuals with Spinal Cord Injury – Maegan Tucker, assistant professor, School of Electrical and Computer Engineering and School of Mechanical Engineering, Georgia Tech; Nicholas Evans (AP 2023), clinical research scientist, Shepherd Center.
• Improving Accessibility and Precision in Neurorehabilitation at the Point of Care with AI-Driven Remote Therapeutic Monitoring Solutions – Brad Willingham, clinical research scientist, director of Multiple Sclerosis Research, Shepherd Center; May Dongmei Wang, professor, Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech.

“Invention is only the beginning. What sets Georgia Tech apart is our ability to move our ideas out of the lab and into the marketplace, where they can make a tangible impact on human life and contribute to our economy,” said Ángel Cabrera, president of Georgia Tech. “This year’s record results show that our researchers aren’t just pushing the boundaries of knowledge — they’re creating marketable solutions with the power to improve everyday lives.”

For fiscal year 2025, Georgia Tech reported:

• More than 460 new invention disclosures — a 30% increase over the previous year and the highest ever recorded by the Institute.
  • 70 invention disclosures for the Georgia Tech Research Institute, marking a 70% increase year over year.
• A 210% increase in technologies licensed, and 140% in total licenses executed, reflecting unprecedented industry interest, with 65 licenses in total.  
• 124 U.S. patents were issued, representing a 20% increase compared to the prior year.
  • According to the most recent rankings from the National Academy of Inventors, Georgia Tech is in the top 15 public universities for U.S. utility patents filed.

This momentum strengthens Atlanta’s position as one of the nation’s fastest-growing innovation economies. Georgia Tech plays a leading role in advancing the region’s ambition to become a top 5 tech hub by connecting world-class research with industry, supporting a thriving startup ecosystem, and fueling talent pipelines that serve emerging sectors like AI, cybersecurity, and clean energy.  

Omer Inan, a Georgia Tech researcher and faculty member, has launched multiple companies with the support of the Institute’s commercialization resources. Cardiosense is a medical AI company that leverages sensors to provide better management of cardiovascular disease. Having just achieved FDA 501(k) clearance, its latest device — CardioTag — is the first multimodal, wearable sensor that simultaneously captures three cardio signals to provide noninvasive solutions for heart health.  

"The med tech research I conduct at Georgia Tech delivers new technologies to keep patients with heart failure out of the hospital and enables them to monitor their health status at home,” said Inan. “Now, we are commercializing the technology our lab helped develop, so that this dream of improving the quality of care and life for millions of Americans with heart failure can one day become reality."

“As we look to solidify Georgia Tech’s status as a national innovation hub, we are moving research into the marketplace so it can truly make a difference in people’s lives,” said Raghupathy “Siva” Sivakumar, vice president of Commercialization and chief commercialization officer at Georgia Tech. “We are at a pivotal moment to put Atlanta on the map as a leader in research commercialization and have an opportunity to capitalize on our $1.4 billion in research expenditures that drive meaningful inventions, IP, and industry partnerships.”  

To learn more about the licensing and commercialization process at Georgia Tech, visit licensing.research.gatech.edu.

Available for Media Interviews

Raghupathy "Siva" Sivakumar 
Vice President of Commercialization and 
Chief Commercialization Officer 
Georgia Tech

Omer Inan 
Professor and Regents’ Entrepreneur  
School of Electrical and Computer Engineering at Georgia Tech

Media Contact: 
Lauren Schiffman       
PressFriendly   
lauren@pressfriendly.com  

Angela Barajas Prendiville   
Director of Media Relations    
Georgia Institute of Technology   
aprendiville@gatech.edu  

 Led by PI: Taylor Higgins, Assistant Professor, FAMU-FSU Department of Mechanical Engineering, partnering with Co-PIs Shreyas Kousik, Assistant Professor, Georgia Tech, George W. Woodruff School of Mechanical Engineering, and Brady DeCouto, Assistant Professor, FSU Anne Spencer Daves College of Education, Health, and Human Sciences, the research will use the acquisition of unicycle riding skill by participants to gain a better grasp on human motor learning in tasks requiring balance and complex movement in space. Although it might sound a bit odd, the fact that most people don’t know how to ride a unicycle, and the fact that it requires balance, mean that the data will cover the learning process from novice to skilled across the participant pool.

Using data acquired from human participants, the team will develop a “robotics assistive unicycle” that will be used in the training of the next pool of novice unicycle riders.  This is to gauge if, and how rapidly, human motor learning outcomes improve with the assistive unicycle. The participants that engage with the robotic unicycle will also give valuable insight into developing effective human-robot collaboration strategies.

The fact that deciding to get on a unicycle requires a bit of bravery might not be great for the participants, but it’s great for the research team. The project will also allow exploration into the interconnection between anxiety and human motor learning to discover possible alleviation strategies, thus increasing the likelihood of positive outcomes for future patients and consumers of these devices.

Author
-Christa M. Ernst

This Article Refers to NSF Award # 2449160

Cabrera introduced Montoya to a professor who could take his work to the next level — Cassie Mitchell, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering (BME). Montoya’s research uses AI to study how robotic exoskeletons and spinal cord stimulation can reawaken dormant neural circuits and help people with paralysis regain sensation, mobility, autonomy, and vital physiological functions once thought permanently lost. Drawing on his experience in leading-edge clinical research, he aims to turn scientific discoveries into real-world solutions that improve independence, quality of life, and health for those with spinal cord injuries. 

It’s not only a curiosity for him, though. In 2012, Montoya was about to graduate from Georgia Tech and become a fighter pilot in the Air Force. Then, one night, he got into a motorcycle accident that left him paralyzed from the chest down. 

Ever since, he has worked to better understand his injury and his options. After earning a master’s in biomedical engineering from Georgia Tech in 2018, Montoya moved to Los Angeles and joined a prestigious neurophysiology and neurorehabilitation lab at UCLA known for pioneering spinal stimulation and activity-based training to restore movement after paralysis. Now he’s taking everything he’s learned back to Georgia Tech.

Mitchell, also a faculty member in the Institute for Neuroscience, Neurotechnology, and Society, applies AI to data science to parse and predict complex medical research. She is also quadriplegic and personally understands the value of spinal cord research. At first, Mitchell mentored Montoya through the BME Ph.D. application process. Now she is his advisor. Montoya starts the program this fall — and he hopes to bring his personal injury recovery insights to the entire spinal cord injury survivor community.

 “My experience as a research participant gives me a unique perspective as I transition into a doctoral researcher,” he said. “It helps me bridge the gap between understanding the science and translating it into real-world clinical practice.”

From Complete Paralysis to Possibility 

Montoya nearly died in the accident. It left him with a complete spinal cord injury and severe peripheral nerve damage in his right arm.

“The doctor told me my spinal cord was like a banana — and mine had been crushed in the middle,” he recalled. “He said I had a 1% chance of regaining any mobility, function, or sensation.”

But Montoya’s life has always been about beating the odds. At 6, he and his father immigrated to the U.S. from Cuba. Years later, he earned a rated pilot slot in the Air Force — a distinction achieved by fewer than 1% of cadets. Then came the motorcycle crash. He flatlined for 15 minutes — a medical event with less than a 1% chance of survival, and even lower odds of returning with full brain function. If anyone was going to defy that prognosis, it was Montoya. He set out not just to walk again, but to rebuild his life and transform his recovery into a blueprint for others to follow.

Exoskeleton Endeavors 

After finishing his master’s at Tech, Montoya went to work with Reggie Egerton, a pioneering neurobiologist at UCLA. With Egerton’s guidance, Montoya experimented with neuromodulation — using electrodes to stimulate the spinal cord. The stimulus helps to excite the neurons below the injury that no longer communicate with the brain. 

While wearing electrodes, Montoya trained in a robotic exoskeleton that progressively reduced its robotic assistance. This encouraged him to contribute increasing effort through each step. Over time, the device provided less support during the swing and stance phases of walking, requiring more active participation. Beyond stepping, Montoya performed standing and weight-shifting exercises, all demanding maximum effort to retrain his nervous system through repetitive, weight-bearing sensory input. 

“Neuromodulation creates a bridge of signals that helps the remaining intact nerve fibers below the injury communicate with each other, enhancing neuroplasticity within the system,” he said.

If the neuromodulation works as intended, it can effectively remodel the nervous system. Through this process and two nerve transfers, Montoya has regained some function in his paralyzed right arm. He has also reversed many common medical complications from paralysis: temperature regulation, body awareness, sexual function, bone density, muscle mass, and digestive health.

“My injury is no longer considered complete, and I believe I’m the first person to achieve that through a combination of spinal stimulation, intensive training, and daily weight-bearing rehabilitation,” Montoya said. “I’m constantly out of my wheelchair — standing, moving, and training. That consistency has been the key. Every day, I walk in an exoskeleton.”

Returning to Georgia Tech

What was supposed to be a 12-month clinical research study turned into the next five years of Montoya’s life. He also wanted to better understand human physiology and how locomotor training worked, so he did a master’s in kinesiology from California State University, Los Angeles. Despite the progress Montoya had made with advancing the field of spinal cord injury and his own mobility, he wanted to bring all his expertise together. That’s when he happened to board a flight to Atlanta in the spring of 2024 with Cabrera.

Initially, Montoya and Mitchell connected so she could help guide him through the Ph.D. application process, but they quickly realized their research was complementary. Montoya is an expert in clinical trials, and Mitchell is an expert in taking clinical trial data and using AI to gather insights. 

“Ignacio wants to diversify his skill set and take his research career further, and data science is what he needs to do that,” Mitchell said. “We will look at his exoskeleton data and try to optimize the exoskeleton to the patient using AI.” 

For the start of his Ph.D., Montoya will remain in Los Angeles to continue his exoskeleton experiments in Edgerton’s lab, which has been collecting terabytes of data he’s never been able to analyze in full. Mitchell’s lab will analyze all that data and pull predictive insights that can feed back to Egerton’s lab and improve the patient experience. 

“AI can identify patterns the human eye wouldn't be able to detect,” Mitchell noted. “AI can help us better understand how and why an exoskeleton paired with spinal stimulation could help with spinal cord injury and function or quality of life.”

Montoya will travel between both coasts to conduct each element of the research before returning to Atlanta full-time. In the process, he’ll build a better knowledge base and exoskeleton training protocol.

This may not have been the path Montoya expected to take when he left Georgia Tech that night in 2012, but it’s a full circle.

“I’m back where my journey paused — this time to push the boundaries of what we believe the human body and spirit can achieve,” he said. “I’m not just walking again. I’m building a future where no one is beyond recovery.”

Christopher Rozell, Julian T. Hightower Chaired Professor in the School of Electrical and Computer Engineering, will serve as the inaugural executive director of Georgia Tech’s new Institute for Neuroscience, Neurotechnology, and Society (INNS). 

In November 2024, JSC granted Assistant Professor Spencer Bryngelson exclusive access to the system through the JUPITER Research and Early Access Program (JUREAP).

By preparing Europe’s fastest supercomputer for launch, the joint project yielded valuable simulation data on the effects of shock waves in medicine and transportation.

“The shock-droplet problem has been a hallmark test problem in fluid dynamics for some decades now. It is sufficiently challenging to study that it keeps me scientifically interested, though the results are manifestly important,” Bryngelson said. 

“Understanding the droplet behavior in some extreme regimes remains an open scientific problem of high engineering value.”

Through JUREAP, JSC engineers tested Bryngelson’s Multi-Component Flow Code (MFC) on their computers. The project simulated how liquid droplets behave when struck by a large, high-velocity shock wave moving much faster than the speed of sound.

Tests produced visualizations of droplets deforming into pancake shapes before ejecting vortex rings as they broke apart from the shock wave. The experiments measured the swirls of air flow formed behind the droplets, known as vorticity.

Vorticity is one variable aerospace engineers consider when building aircraft designed to fly at supersonic and hypersonic speeds. Small droplets and vortices pose significant hazards for high-Mach vessels.

These computer models reduce the risk and cost associated with physical test runs. By simulating extreme scenarios, the JUREAP project demonstrated a safer and more efficient way to evaluate aerospace systems.

The human body is another fluid space where fast, high-energy flows can occur.

Simulations help medical researchers create less invasive shock wave treatments. This technology can be further applied for uses ranging from breaking up kidney stones to treating inflammation. 

MFC’s versatility for large- and small-scale applications made it suitable for testing JUPITER in its early stages. The project’s success even earned it a JUREAP certificate for scaling efficiency and node performance.

“The use of application codes to test supercomputers is common. We’ve participated in similar programs for OLCF Frontier and LLNL El Capitan,” said Bryngelson, a faculty member with Georgia Tech’s School of Computational Science and Engineering.

“Engineers at supercomputer sites usually find and sort most problems on their own. But deploying workloads characteristic of what the JUPITER will run in practice stresses it in new ways. In these instances, we usually end up identifying some failure modes.”

The JSC and Georgia Tech researchers named their joint project Exascale Multiphysics Flows (ExaMFlow).

ExaMFlow helps keep JUPITER on pace to become Europe’s first exascale supercomputer. This designation refers to any machine capable of computing one exaflop, or one quintillion (“1” followed by 18 zeros) calculations per second. 

All three systems that rank ahead of JUPITER are exascale supercomputers. They are El Capitan at Lawrence Livermore National Laboratory, Frontier at Oak Ridge National Laboratory, and Aurora at Argonne National Laboratory. 

JUPITER calculates more than 60 billion operations per watt. This makes the supercomputer the most energy-efficient system among the top five. 

ExaMFlow ran Bryngelson’s software on JSC’s JUWELS Booster and JUPITER Exascale Transition Instrument (JETI). The two modules form the backbone of JUPITER’s full design.

ExaMFlow’s report showed that MFC performed with near-ideal scaling behavior on JUWELS and JETI compared to similar systems based on NVIDIA A100 GPUs.

Access to NVIDIA hardware at Georgia Tech played a key role in ExaMFlow’s success.

The Institute hosts the Phoenix Research Computing Cluster, which includes A100 GPUs among its arsenal of components. Bryngelson’s lab owns NVIDIA A100 GPUs and four GH200 Grace Hopper Superchips. 

Since JUPITER is equipped with around 24,000 Grace Hopper Superchips, Bryngelson’s work with the hardware proved especially insightful for the ExaMFlow project.   

“The Grace Hopper chip is interesting. It’s not challenging to use like a regular GPU device when one is familiar with running NVIDIA hardware. The more fun part is using its tightly coupled CPU to GPU interconnect to make use of the CPU as well,” Bryngelson said. 

“It’s not immediately obvious how to best do this, though we used a few tricks to tune its use to our application. They appear to work nicely.”

JSC researchers Luis Cifuentes, Rakesh Sarma, Seong Koh, and Sohel Herff played important roles in running Bryngelson’s MFC software on early JUPITER modules. 

The ExaMFlow team included NVIDIA scientists Nikolaos Tselepidis and Benedikt Dorschner. 

The pair observed their company’s hardware used in the field. They return to NVIDIA with notes that help the corporation build the next devices tailored to the need of scientific computing researchers. 

“We try to be prepared for the latest, biggest computers. Being able to take immediate advantage of the largest systems is a valuable capability,” Bryngelson said. 

“When the early access systems arrive, it’s a great opportunity for the teams involved to test the machines, demonstrate and tune scientific software, and meet very capable new collaborators.”

Along with insulin, it also could be used for semaglutide — the popular GLP-1 medication sold as Ozempic and Wegovy — and a host of other top-selling protein-based medications like antibodies and growth hormone that are part of a $400 billion market.

These drugs usually have to be injected because they can’t overcome the protective barriers of the gastrointestinal tract. Georgia Tech’s new capsule uses a small pressurized “explosion” to shoot medicine past those barriers in the small intestine and into the bloodstream. Unlike other designs, it has no complicated moving parts and requires no battery or stored energy.

“This study introduces a new way of drug delivery that is as easy as swallowing a pill and replaces the need for painful injections,” said Mark Prausnitz, who created the pill in his lab with former Ph.D. student Joshua Palacios and other student researchers. 

In animal lab tests, they showed their capsule lowered blood sugar levels just like traditional insulin injections. The researchers reported their pill design and study results DATE in the Journal of Controlled Release.

Read about the technology on the College of Engineering website.

READ THE ARTICLE

As temperatures and humidity levels rise in the summer months, hydration and heat acclimatization become increasingly vital in maintaining physical and mental health and maximizing performance.   

“Malaria kills over 500,000 annually with the mortality rate substantially higher in Africa,” says Frooman. “Our research explores how specific peptides bind to proteins that trigger immune responses.”

Frooman originally hoped the research would help her learn how to think like a scientist and gain basic lab knowledge.

She gained those skills and more, quickly becoming recognized as an exceptional researcher.

“Marielle is one of the most passionate and talented undergraduate researchers I have ever worked with,” says Andrew McShan, McShan Lab principal investigator and associate professor in the School of Chemistry and Biochemistry. “She is also a caring mentor and motivated future leader who wants to change the world. Her malaria research has the potential to provide real therapeutic outcomes, including better designs for vaccines and immunotherapy.” 

From curiosity to contribution

Frooman’s journey into undergraduate research began with persistence. After a year and a half of searching for lab opportunities, she attended a School of Chemistry and Biochemistry research showcase. She approached several graduate students and professors with no success, until she met McShan.

“Our first meeting was so relaxed and friendly that I didn’t even realize Professor McShan was the principal investigator,” admits Frooman. “That’s how it all started.”

Once she officially joined the lab, Frooman contributed to every stage of the research, including designing experiments, performing computational and wet lab work, analyzing data, and writing and presenting the paper.

Lessons in resilience

The team faced several challenges.

“The research was delayed by failure after failure,” says Frooman. “But each setback taught us something valuable.”

The team’s biggest challenge involved trying to grow crystals of the peptide/HLA (protein) complexes to determine how they fit together. They spent two years attempting various methods, but nothing worked.

Guided by McShan, Frooman and the team then came up with the idea of using computational modeling to enable a deeper understanding of how the peptides and proteins interact at both biophysical and structural levels.

“Utilizing the computational modeling enabled us to see the best bindings and turned into a game-changing insight for our research, potentially leading to the design of more effective malaria treatments and vaccines,” explains Frooman.

She is quick to credit Georgia Tech and McShan for providing her with such a valuable learning experience.

“At many universities, undergraduates rarely do meaningful research, but at Tech, it’s a priority,” explains Frooman. “I’m extremely grateful for the opportunity to grow in such a supportive environment, and to learn from mentors like Professor McShan who lead by example and make time for every student.”

Her advice to other undergraduates entering research?

“Embrace your failures. They make the successes even more rewarding,” shares Frooman.

Outside the lab

On campus, Frooman is president of the Student Affiliates of the American Chemical Society and Cleanup Crew at GT, a member of Alpha Phi International Fraternity, and a campus tour guide who serves on their executive board. 

She especially loves being a tour guide as it allows her to share her love of Georgia Tech and its people:

“Everyone is unapologetically themselves and fully invested in their major or interests. As someone who loves chemistry, I enjoy being surrounded by people who are just as dedicated to their passions.”

Frooman is a recipient of the Chance Family Scholarship, presented to two School of Chemistry and Biochemistry upperclassmen, recognizing their academic excellence, research contributions, and potential for career success in the field.

Recently, she shifted her research focus to organic synthetic chemistry and now works in the Gutekunst Lab. Her career goals include earning a Ph.D. in Chemistry with an emphasis on natural product synthesis, the lab-based creation of complex chemical compounds found in nature.

“I’ve seen what university labs can do,” says Frooman. “I hope to one day lead my own lab, advancing impactful research and mentoring the next generation of scientists.”

Read the full press release here. 

Citation: Robert G. Mannino, Julie Sullivan, Jennifer K. Frediani, Wilbur A. Lam. “Real-world Implementation of a Noninvasive, AI-augmented, Anemia-screening Smartphone App and Personalization for Hemoglobin Level Self-monitoring,” PNAS. DOI: 10.1073/pnas.2424677122

A team of researchers at Georgia Tech has addressed this challenge, creating a new way to predict how these cutting-edge treatments might work in a particular patient. And it could revolutionize treatments for kids with complex immune system challenges.

Read full story here. 

Ph.D. candidate Md Abdur Rahaman’s dissertation studies brain data to understand how changes in brain activity shape behavior. 

Computational tools Rahaman developed for his dissertation look for informative patterns between the brain and behavior. Successful tests of his algorithms show promise to help doctors diagnose mental health disorders and design individualized treatment plans for patients.

“I've always been fascinated by the human brain and how it defines who we are,” Rahaman said. 

“The fact that so many people silently suffer from neuropsychiatric disorders, while our understanding of the brain remains limited, inspired me to develop tools that bring greater clarity to this complexity and offer hope through more compassionate, data-driven care.”

Rahaman’s dissertation introduces a framework focusing on granular factoring. This computing technique stratifies brain data into smaller, localized subgroups, making it easier for computers and researchers to study data and find meaningful patterns.

Granular factoring overcomes the challenges of size and heterogeneity in neurological data science. Brain data is obtained from neuroimaging, genomics, behavioral datasets, and other sources. The large size of each source makes it a challenge to study them individually, let alone analyze them simultaneously, to find hidden inferences. 

Rahaman’s research allows researchers and physicians to move past one-size-fits-all approaches. Instead of manually reviewing tests and scans, algorithms look for patterns and biomarkers in the subgroups that otherwise go undetected, especially ones that indicate neuropsychiatric disorders.

“My dissertation advances the frontiers of computational neuroscience by introducing scalable and interpretable models that navigate brain heterogeneity to reveal how neural dynamics shape behavior,” Rahaman said. 

“By uncovering subgroup-specific patterns, this work opens new directions for understanding brain function and enables more precise, personalized approaches to mental health care.”

Rahaman defended his dissertation on April 14, the final step in completing his Ph.D. in computational science and engineering. He will graduate on May 1 at Georgia Tech’s Ph.D. Commencement. 

After walking across the stage at McCamish Pavilion, Rahaman’s next step in his career is to go to Amazon, where he will work in the generative artificial intelligence (AI) field. 

Graduating from Georgia Tech is the summit of an educational trek spanning over a decade. Rahaman hails from Bangladesh where he graduated from Chittagong University of Engineering and Technology in 2013. He attained his master’s from the University of New Mexico in 2019 before starting at Georgia Tech. 

“Munna is an amazingly creative researcher,” said Vince Calhoun, Rahman’s advisor. Calhoun is the founding director of the Translational Research in Neuroimaging and Data Science Center (TReNDS).

TReNDS is a tri-institutional center spanning Georgia Tech, Georgia State University, and Emory University that develops analytic approaches and neuroinformatic tools. The center aims to translate the approaches into biomarkers that address areas of brain health and disease.    

“His work is moving the needle in our ability to leverage multiple sources of complex biological data to improve understanding of neuropsychiatric disorders that have a huge impact on an individual’s livelihood,” said Calhoun.

McShan, an assistant professor in the School of Chemistry and Biochemistry, has been awarded a $1.4 million CAREER grant from the National Science Foundation (NSF) to support this research.

“Protein-lipid assemblies carry out all sorts of biological functions, and harnessing their interactions could lead to powerful tools and treatments — but historically, they’ve been difficult to study,” McShan says. “Building resources for researchers and making this information accessible are critical steps in developing this field. This CAREER grant will enable me to expand the current knowledge base, while also allowing me to develop a class that will train the next generation of researchers, which is hugely important to me.”

The NSF Faculty Early Career Development Program is a five-year grant designed to help promising researchers establish a foundation for a lifetime of leadership in their field. Known as CAREER awards, the grants are NSF’s most prestigious funding for early-career faculty.

Expanding access

Crucial for nearly all biological processes, lipid-protein interactions play a key role in everything from immune responses to energy storage — but what drives their interactions has historically been difficult to map and understand.

McShan will use the CAREER grant to expand that knowledge base, experimenting in the lab to characterize protein-lipid interactions, and developing computational tools that can predict those interactions. The work will include an in-depth study of how lipids interact with different families of proteins that are important for immune system function.

“Right now, understanding protein-lipid assemblies is expensive in both time and lab materials,” McShan says. “My goal is to create computer models that can predict how these biomolecular interactions occur, what they look like, and how they contribute to cellular functions.”

The new model would allow researchers to quickly and inexpensively ‘experiment’ with molecules on a computer, vastly expanding the amount of research that could be conducted. 

The project builds on McShan’s recent publication in the Nature-family journal Communications Chemistry, which showcased BioDolphin — a first-of-its-kind, comprehensive, and annotated database of protein-lipid interactions that are all integrated into a user-friendly web server and freely accessible to all. 

It’s also adjacent to research funded by a Curci Grant from the Shurl and Kay Curci Foundation, which McShan was previously awarded for research on cutting-edge cancer treatments that involved identifying new cancer lipid signatures in tumor cells, and characterizing known cancer lipid antigens.

Pioneering the future of research

Additionally, the CAREER grant will support McShan’s initiatives to train the next generation of researchers through a new class centered around hands-on laboratory research and peer mentorship. Students will have the opportunity to pick a protein-lipid assembly, study it using computational and experimental biophysical methods, develop testable hypotheses, and — if successful — publish their results in peer reviewed journals.

The class will also pair undergraduate and graduate students into research teams. “I’m excited to see how a peer mentoring approach will add depth to the class,” McShan shares, explaining that graduate students will gain valuable mentoring experience in a collaborative research environment. “This is very different from typical mentoring experiences many graduate students have, which tend to be more along the lines of a TA experience rather than collaborating on hands-on research.”

“This type of class, to my knowledge, hasn’t been offered before, and there’s a lot of research that I’m doing to lay the groundwork for it,” McShan adds. “Hopefully, it can not only introduce students to lipid-based research — something typically lacking in many biochemistry curricula — but also to the type of collaborative mentorship we want to foster in research.”

The Society for Industrial and Applied Mathematics (SIAM) selected Elizabeth Cherry and Katya Scheinberg as Class of 2025 fellows. The two Georgia Tech faculty join an illustrious class of 23 other researchers from around the globe in this year’s class. 

SIAM selected Cherry to recognize her contributions to mathematical and computational modeling and extensive service to the SIAM community. She studies the electrical behavior of cardiac cells and tissue.

Cherry’s computer models and simulations improve understanding of cardiac dynamics in normal and diseased states. Using these tools, she designs advanced strategies for preventing and treating arrhythmias.

“SIAM has played a huge role in my professional development—the first conference I attended as a graduate student was a SIAM conference, and I’ve attended at least one SIAM conference almost every year since then,” Cherry said. 

“Given this long history, it means a lot to me for SIAM to acknowledge my contributions in this way.”

Scheinberg, from Georgia Tech’s College of Engineering, was selected for her foundational contributions to derivative-free optimization and optimization applications in data science and her dedicated service to the optimization community.

[Related: Coca-Cola Foundation Chair Katya Scheinberg selected for 2025 Class of SIAM Fellows]

Cherry is the fifth faculty member from the School of Computational Science and Engineering (CSE) to be selected as a SIAM Fellow.

Cherry’s announcement as a SIAM Fellow comes weeks after serving in a leadership role at a SIAM conference. She co-chaired the organizing committee of the SIAM Conference on Computational Science and Engineering (CSE25).

In 2023, SIAM members reelected Cherry to a second term as a council member-at-large. She began her three-year term in January 2024.

"SIAM Fellows are selected for deep mathematical contributions. Receiving Fellow status is a high honor for any applied mathematician," said Regents’ Professor Srinivas Aluru, senior associate dean of the College of Computing and Class of 2020 SIAM Fellow. 

"Not only are Elizabeth's contributions technically outstanding, but her work also provides deep insights into the functioning of the heart and its abnormalities."

Cherry’s leadership and service extends outside of SIAM, influencing students and faculty across Georgia Tech. 

In December, the College of Computing appointed Cherry as associate dean for graduate education. Before this appointment, she served as associate chair for academic affairs of the School of CSE. 

With her new role as associate dean, Cherry continues serving as director of CSE programs at Georgia Tech. 

In March 2024, Cherry was among five Georgia Tech faculty members selected for the ACC Academic Leaders Network (ACC ALN) Fellows program. The ALN program fosters cross-institutional networking and collaboration between ACC schools, increasing each institution’s academic leadership capacity.

Cherry was part of a team of Georgia Tech and Emory University researchers who won a Georgia Clinical and Translational Science Alliance award in 2023. The group earned the Team Science Award of Distinction for Early Stage Research Teams award for work that captures high-resolution visualizations of spiral waves that create heart arrhythmias.

SIAM will recognize Cherry, Scheinberg, and Class of 2025 fellows during a reception at the SIAM/CAIMS Annual Meetings this July in Montréal.

“It is such an honor to be recognized as a SIAM Fellow,” Cherry said. “I’m thrilled to join my CSE colleagues who have also received this recognition.”

“You can’t go it alone,” said Yunker, an associate professor of physics at Georgia Tech. 

In January, Yunker co-founded the biotechnology startup TopoDx LLC, with David Weiss, an Emory University School of Medicine researcher and director of the Emory Antibiotic Resistance Center, and Yogi Patel, a Georgia Tech alumnus with a background in business development and bioengineering. 

“Researchers often think that they have a good commercialization idea to help people, but that alone does not guarantee success,” said Yunker. “Look for partners with complementary skills who understand aspects of the commercialization process that you don’t. Find mentors with business and scientific backgrounds in the specific industry you want to enter.”

TopoDx has developed a microbial test to identify antibiotic resistance and susceptibility rapidly and accurately. Current tests produce a result in three to five days. TopoDx’s approach can gain a result within four hours. Every hour counts in treating serious infections. Delays in accurate treatment can increase antibiotic resistance, which is a global challenge, causing up to 1 million deaths a year. 

The company’s testing method was inspired by a fundamental biophysics project in Yunker’s lab. His team was interested in understanding how bacterial colonies behave. They tested white-light interferometry, a technology that can measure bacterial colonies down to the nanometer level. 

“White-light interferometry allowed us to identify changes in the topography of a colony that indicated larger changes in the volume of cells in the entire colony,” said Yunker. “We thought this might have practical applications.” 

The next step was giving research talks at meetings and looking for collaborators. “I wanted to find someone with expertise on the bacteriology side, and I was very fortunate to meet David Weiss,” Yunker said, noting his proficiency in heteroresistance, a phenomenon where a small subset of a bacterial colony resists an antibiotic. 

“If you have just one antibiotic-resistant cell in a hundred cells, it can cause treatments to fail,” said Yunker. 

The two collaborators hoped to commercialize their technology, identifying heteroresistance in microbial samples. However, they needed guidance in creating a business model. They consulted Harold Solomon, an entrepreneur with Georgia Tech VentureLab and a principal in the Quadrant-i program, a specialized program helping Georgia Tech faculty and students commercialize research.  

Solomon became a key mentor. He guided them away from an ill-advised partnership and instead introduced them to Yogi Patel, who became a co-founder and the company CEO. 

This new collaboration provided the team with an important lesson — one that Yunker passes along to other researchers looking to commercialize their discoveries. “Seek expertise outside your field, be humble about your knowledge limitations, and view collaboration as a strategic partnership,” he says.

When Patel came on board, he conducted extensive interviews with more than 15 clinical professionals.

“You need to interview end users or purchasers of whatever solution you want to build,” said Patel. “Ask them if the problem you think you may have solved is a problem with scale, with a market need.” 

Clinicians, Patel learned, did not see heteroresistance as a significant issue. Instead, the slow pace of antibiotic testing was identified as a major problem. Faster testing could allow clinicians to prescribe targeted drugs more quickly and accurately, reducing unnecessary antibiotic use and the risk of multi-resistant infections. 

With this survey information, Patel asked Yunker and Weiss to rethink how their technology could be commercialized. 

“A company must solve a real-world problem,” said Patel. “I recommended that we switch from heteroresistance to solving slow antibiotic testing. We could keep heteroresistance as something we can still do as a second or third priority.” 

TopoDx’s new technology can measure, with single-nanometer accuracy, how bacterial colonies are responding to antibiotics in real time. This method could revolutionize how antibiotics are tested and prescribed. Testing would be conducted on a countertop device about the size of a large microwave. The co-founders envision the device as eventually being used by urgent care facilities and hospitals. 

“We want to make microbial testing susceptibility accessible anywhere and everywhere,” said Patel.   

Adam Krueger, once a Ph.D. student in Yunker's lab, has continued to refine the technology. Now a post-doctoral researcher, Krueger joined TopoDx in a technical leadership role to expand the technology’s capabilities for microbiological diagnostics.

“We will keep pushing the envelope forward scientifically while we try to commercialize the accomplishments that we have already made,” Yunker said. “We hope that some fundamental studies we are doing now out of scientific curiosity could lead to further commercial applications.”

Georgia Tech faculty members and graduate students, join the Quadrant-i Startup Launch Program to commercialize your research this summer: Over 12 weeks, you'll receive comprehensive support including guidance from experienced mentors, a $10,000 commercialization grant, and $150,000 worth of in-kind services. Showcase your innovation at Demo Day, where you'll have the opportunity to present to over 1,500 attendees, including industry leaders and investors. Apply today! Applications close April 11.

A team of biomedical engineering students represented Georgia Tech at the ACC InVenture Prize Competition in South Bend, Indiana, pitching an invention that could improve wound care for chronic patients and efficiency in healthcare systems.  

That’s miniaturization science for you. It’s the study of how materials and systems behave at microscopic scales, and it’s transforming biomedical engineering. And though it has led to breakthroughs in diagnostics and treatments, “teaching students about the subject is really challenging,” said David Myers, assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory. 

“It’s because the behavior of fluids and materials at such small scales defies intuition, and you can’t really observe what’s going on,” added Myers, who understands the instructional challenge well — he teaches a graduate level course focused on translational microsystems, which is heavily integrated with his lab’s research. 

Recognizing the limitations of traditional coursework, Myers and his collaborators have developed a different approach. In Myers’ class, students build and test and observe the workings of microfluidic devices, a hallmark of miniaturization science — microfluidics is the manipulation of tiny volumes of fluids in miniaturized devices. 

Their new approach has made all the difference, even earning Myers a CIOS Award for teaching excellence. But Myers is quick to emphasize that this was a team effort. He and his lab developed a hands-on activity to help students learn device construction (and the underlying technical concepts). 

Then he reached out to Todd Fernandez, senior lecturer and Coulter BME’s director of learning innovation. Together they optimized the activity to maximize students’ learning. That has evolved into an ongoing partnership between technical and educational research faculty in the department, resulting in an article in the journal Lab on a Chip. 

"In other microfluidics courses, you walk through the step-by-step process of fabrication, but actually seeing the device come together in front of you provides such valuable insight into the underlying concepts and manufacturing techniques,” explained Priscilla Delgado, a fifth-year graduate student in Myers’ lab and lead author of the published study. “That hands-on experience is crucial for truly understanding this technology."

Bridging Critical Gaps

Myers’ course bridges several critical gaps, including the high cost of advanced learning activities. It also addresses student misconceptions. 

“The primary objective isn’t just the successful construction of devices, but a deeper conceptual understanding of miniaturization science and design principles,” said Myers, whose approach emphasizes conceptual change. 

Students often come into the course with misunderstandings about microscale phenomena, “assuming that fluid flow at this scale behaves the same way as in larger systems,” Myers said. 

Delgado added, “but it’s wild how fluid behavior changes at the microscale. If you mix two colored liquids in a regular cup, you get a third color. But in microfluidics, the laminar flow and reliance on diffusion can keep those streams separate — it really challenges your intuition about mixing.”

The class allows students to build and test microfluidic kits — mixers, valves, and bubble generators, using inexpensive, widely available materials. This activity is structured to help students encounter misunderstandings and work through them. Rather than simply presenting correct information, instructors guide students through a learning cycle in which they identify errors, reflect on their mistakes, and refine their understanding. 

“You can see their brains just sizzle,” said Myers. “Then you kind of add a little bit of structure. You ask, ‘Are you sure you have all the layers there that you’re thinking about?’ And then they’ll go back, count, and realize—oh, there’s this missing middle layer.”

The layer-by-layer assembly technique uses laser-cut adhesive films to construct microfluidic devices. Because the devices are assembled from transparent layers, students can see how their designs function and they can troubleshoot any errors. 

“One of the best things about these sticker-based microfluidic devices is how easy they are to prototype,” said Delgado. “I can literally have a new design laser-cut and assembled within an hour, rather than waiting months using traditional methods. The accessibility and speed of iteration is a game-changer."

Expanding the Possibilities

Beyond its accessibility, the sticker-based microfluidic approach also expands the possibilities for innovation. 

“The really cool thing is, this is a sticker,” Myers said. “You can place it on your skin. You can place it on the table. You can place it on the wall, if you really felt like it. And when you integrate it with high-end instrumentation like advanced sensors, suddenly you have a resource that traditional microfluidics can’t easily replicate.”

This kind of flexibility enables students to explore microfluidics in new ways. The study involved 57 students, some of whom took their designs beyond the classroom. 

“I cannot say enough how much I love how accessible it is and the portability of it,” Delgado said. “You can do this anywhere. You could do this at home. We’ve done it at science fairs for high school students to really challenge the way they think about mixing.”

The impact of the work has also influenced the direction Delgado wants to take in her career. She’s found herself drawn deeper into the field, inspired by microfluidic design. 

“The first time I laid eyes on that microfluidic device I had just built, I was captivated,” she said. “I remember thinking, ‘This is so cool; I have to dive deeper into this field.’ That’s when I knew a PhD was in my future, even though I had initially planned otherwise.”

This approach to teaching miniaturization science not only enhances learning but also democratizes access to innovation, according to Myers.

“The really cool thing that I love about this activity is that you’re sharing knowledge and power with the people using the technology,” he said. “Instead of them receiving technology from some high-resource institution, they’re able to look at the problems and start addressing them themselves.”

Miniaturization science plays a crucial role in developing point-of-care medical devices and other low-cost diagnostic tools, particularly in resource-limited settings. Equipping students around the world with the ability to create microfluidic systems could help empower future researchers and engineers.

Fernandez believes this hands-on approach represents a shift in how miniaturization science will be taught. 

“By focusing on student-driven exploration and conceptual understanding rather than rote device assembly, educators can better prepare the next generation of engineers and scientists to navigate and contribute to the ever-expanding world of microsystems,” he said. “ And what’s really cool is, you let them play, and they learn more. They discover things that we didn’t even have time to teach them.”

Georgia Tech stands on the brink of a medical revolution, fueled by a monumental award from the Marcus Foundation. This transformative $40 million endeavor, with a principal investment of $20 million from the Marcus Foundation, promises to make high-quality, life-saving cell therapies more affordable, reliable, and accessible than ever before. 

Currently, there are nine students in the Cardiovascular Biomechanics Graduate Training Program at Emory and Georgia Tech (CBT@EmTech). The program offers two years of training in an assortment of disciplines, including cardiovascular biomechanics, mechanobiology, medical imaging, computational modeling, medical devices, therapeutics discovery and delivery, and data science.

“The goal of the program is to stimulate interdisciplinary training,” so we expose the students to multiple areas of research,” says Hanjoong Jo, CBT@EmTech director, Wallace H. Coulter Distinguished Professor. 

“And we have a very diverse group of trainees interested in various aspects of cardiovascular research and medicine,” Jo added. “Four out of five students from our first cohort already have secured prestigious fellowships, demonstrating the caliber of the trainees in the program.”

The students from that cohort brought a wide range of experiences, interests, and ambitions to the program. Now in their final months as CBT@EmTech trainees, they took time to share their stories.

Yohannes Akiel

Principal Investigator: Michael Davis

Campus: Emory

Undergraduate: University of Texas-San Antonio
I've always had a passion for helping people and I feel that I’m doing this through my research on aortic valve tissue engineering for pediatric patients. Aortic valve disease is found in 1-2% of live births, because of congenital heart defects or infections. Current valve replacements are limited — for one thing, they’re incapable of growing and remodeling with the patient. This presents a need for a new tissue-engineered valve that can address these challenges. In the Davis lab, we’re working on a tissue engineered heart valve to provide a better, long-term solution. 

Throughout my time in the CBT@EmTech program, I've gained a range of knowledge in the cardiovascular space, learning about atherosclerosis, peripheral artery disease, valve disease, as well as computational and imaging techniques to help solve some of these problems. As part of the program, we are also required to take an Advanced Seminar class in the cardiovascular area. 

Through this class, I was able to participate in some interesting clinical observations in the Emory University Hospital cardiology department. For example, I watched a cardiologist perform a transesophageal echocardiogram. The doctor was checking for heart blockages on a patient who had atrial fibrillation. This procedure was followed by a cardioversion to restore a normal heart rhythm. This was a profound demonstration of biomedical technology in action that left a lasting impression on me.

Leandro Choi

Principal Investigator: Hanjoong Jo

Campus: Emory

Undergraduate: Duke University

As a PhD student in the Jo Lab, I am studying how disturbed flow influences transcriptional regulation in endothelial cell reprogramming and atherosclerosis. Our goal is to identify and develop therapeutics that target non-lipid residual pathways contributing to this widespread and deadly disease. 

I initially became interested in this line of research due to a family history of cardiovascular disease. As an undergraduate, I worked in a tissue engineering lab where I employed stem cell and tissue engineering methods to model the circulatory system. A desire to further explore the role of mechanosensitive genes and proteins in cardiovascular disease led me to pursue a PhD in this field.

One of the most valuable aspects of the CBT@EmTech program has been the opportunity to connect with a network of students and faculty who are leaders in cardiovascular research. Through monthly meetings, we share our work and gain insights into the diverse engineering applications our interdisciplinary program brings to the field, with the common goal of improving cardiovascular health.

Aniket Venkatesh

Principal Investigator: Lakshmi Prasad

Campus: Georgia Tech

Undergraduate: Georgia Tech

 October 2024 marked the three-year anniversary of my uncle’s passing due to complications from a mild heart attack. His angiogram showed 30% vessel blockage, leading to heart surgery. Sadly, he suffered a brain stroke days later, resulting in deteriorating speech, muscle movement, and eventually death at 48. This personal tragedy brought urgency to my research questions: Can the risk of complications following cardiovascular treatments be predicted? Can underlying cardiovascular pathology be treated before it progresses to a heart attack or stroke? Was my uncle’s death preventable? These questions drive my cardiovascular research, focused on predicting post-procedural heart valve outcomes through computational modeling.

Being part of the prestigious CBT@EmTech program at Emory and Georgia Tech has significantly advanced my research journey. Learning from fellow trainees, presenting my research, and attending academia-focused workshops (like one about grant writing) have helped me stand out in heart valve computational modeling. The program, along with my PI, Dr. Lakshmi Prasad Dasi, and co-PI, Dr. John Oshinski, has provided the resources needed to translate my research from the lab to the clinic through regular meetings with clinicians and data transfer to and from hospitals. I am grateful for the opportunity to pursue my long-term goal of predicting risks of complications before cardiovascular treatments and helping prevent adverse clinical outcomes like those experienced by my uncle.

Isabel Wallgren

Principal Investigator: Simone Douglas-Green

Campus: Georgia Tech

Undergraduate Degree: University of Virginia

Peripheral artery disease (PAD) occurs when atherosclerotic plaque accumulates in limb arteries, blocking blood flow. Current interventions limit disease progression, but surgery is often needed to prevent critical limb ischemia. A less invasive approach promotes angiogenesis and arteriogenesis to strengthen collateral vessels and bypass blockages. The Hansen Lab studies satellite cells (SCs), which repair muscle fibers and release growth factors, as a potential PAD therapy.

My research focuses on improving the delivery of SCs using a special fibrin scaffold in a mouse model of blocked blood flow in the legs. By adjusting the properties of the fibrin scaffold, we can create an environment that helps these cells grow and renew themselves. We study how quickly the fibrin forms to ensure the cells stay where we inject them and how it breaks down to keep a steady supply of renewing SCs. We believe that with fibrin, the cells will move into the damaged tissue, repair muscle fibers, and release growth factors to encourage new blood vessel growth.

The goal is to create alternative treatments for PAD that prevent disease progression and improve patients' quality of life.

The CBT@EmTech program has given me a supportive network of peers and mentors, enhancing my growth as a researcher. The program chairs have tailored the curriculum to our needs and allowed us to shape it. For example, I’ve had the privilege of co-planning our biannual retreat. We recruited guests for two panels and invited a guest speaker for a storytelling workshop. This retreat shows how the program imparts knowledge beyond research, aiming to improve our scientific storytelling and self-presentation skills, valuable for any career.

Deborah Wood

Principal Investigator: Simone Douglas-Green

Campus: Georgia Tech

Undergraduate Degree: University of Virginia

As a researcher, I am challenged to explore the unknown. Moreover, my role as an engineer is rooted in using knowledge that has already been conceptualized. Combining these perspectives as a biomedical engineer has led me to pursue research with an emphasis on improving human health.

Today, cardiovascular diseases represent the global leading cause of death. While this glaring statistic indicates the egregious burden of cardiovascular diseases, my parents' lived experiences with cardiovascular diseases is what drives me to use my life’s work to address critical challenges at the intersection of the cardiovascular field and biomedical engineering. 

My research seeks to alleviate cardiovascular diseases by using nanoparticles to target endothelial cells, which line the innermost layer of blood vessels and contribute to blood vessel function. The Cardiovascular Biomechanics and Mechanobiology Program at Emory (CBT@EmTech) has given me an avenue to pursue this research. 

Through my CBT@EmTech co-mentorship, I have developed a foundation in endothelial cell biology and atherosclerosis. I have also been challenged to think critically about how my research benefits both science and society through my exposure to prominent cardiovascular researchers. My experiences with CBT@EmTech have made me eager to use my training to pursue a postdoc in the and eventually lead a lab answering critical questions in cardiovascular research.

Georgia Tech’s Pediatric Innovation Network (PIN) has collaborated with Shriners Children’s since 2017. The initiative connects researchers — including engineers, data analysts, scientists, and others — with frontline pediatric clinicians to create new technologies for unmet pediatric healthcare needs. This dynamic collaboration began with a conversation between Marc Lalande, vice president of research at Shriners’ Children’s, and Leanne West, chief engineer of pediatric technologies at Georgia Tech, who were introduced by a mutual colleague. 

That conversation has resulted in 22 projects to date, spanning topics such as artificial intelligence, data management, robotic exoskeletons, augmented reality games, wearable sensors, and more. The collaboration between Shriners Children’s and GT PIN works to engage faculty and students within Georgia Tech’s cutting-edge research ecosystem and multiple hospitals within Shriners’ network.

“From the very beginning, this has been an amazing collaboration. Our faculty love working on the real-world problems brought to us by Shriners’ clinicians,” said West.

Learn more about one of these projects on how virtual reality is transforming assessment of patients with upper limb movement challenges.

Raquel Lieberman, a professor in the School of Chemistry and Biochemistry and the Parker H. Petit Institute for Bioengineering and Bioscience, and her lab team have discovered two new antibodies with promise to treat glaucoma. The antibodies can break down the protein myocilin, which, when it malfunctions, can cause glaucoma.

Lieberman’s group recently published this research in the Proceedings of the National Academy of Sciences: Nexus.

Protein Problems

Myocilin is just one of hundreds of thousands of proteins that make up the human body. In the eye, an especially delicate balance of proteins and fluid enables sight. The aqueous humor, a clear fluid, bathes the lens that helps focus light into the retina. In a healthy eye, the fluid drains regularly, but if something prevents the fluid from circulating, it increases pressure.

“Your eyeball is kind of like a basketball,” explained Lieberman. “If you want it to work optimally, it has to be pressurized.” 

Lieberman’s team has learned that if myocilin mutates, it clumps up and prevents aqueous humor from draining, increasing eye pressure. If left unmanaged, glaucoma and — eventually — blindness will occur. 

Antibody Answer

Lieberman’s lab characterized two new antibodies that each, in their unique way, can destroy myocilin gone rogue. One binds in a way that does not prevent myocilin from clumping; the other prevents the protein from aggregating. Both effectively break down myocilin so it no longer blocks the aqueous humor from flowing. 

“These exciting results provide proof of concept that targeted antibodies for mutant myocilin aggregation could be therapeutic,” said Alice Ma, a Ph.D. graduate who worked on the research. “This represents a new paradigm for treating other diseases associated with protein clumping, like Alzheimer’s. These studies hold the potential to save the eyesight of millions of glaucoma patients.”

The findings have been the culmination of nearly two decades of research with Lieberman’s close collaborator, University of Texas at Austin chemical engineering Professor Jennifer Maynard, whose group helped discover the two antibodies that responded to the mutation. Lieberman’s group then worked to understand how the antibodies functioned, determining the two that most successfully broke down the protein. 

“This study builds on 10 years of work that explains how myocilin folds to how to break it down,” Lieberman said. “I am at a very fortunate place in my career where this fundamental research coalesces into what we could use clinically.”

Treatment Transformation

Lieberman hopes the antibodies can help treat glaucoma patients, particularly those with early onset glaucoma, often children. She now has a research collaboration with Rebecca Neustein, a physician at Emory University who treats these young patients. 

“She doesn't have much hope to give her patients for curing glaucoma,” Lieberman said. “So she was very excited that we could do some genotyping and figure out who these antibodies can help.”

Lieberman’s research offers a clearer future for millions suffering from glaucoma and those at risk of developing the disease. By leveraging antibodies to target and break down malfunctioning myocilin, this discovery not only paves the way for new treatments for glaucoma but also opens doors for addressing other protein-aggregation diseases like Alzheimer’s, Parkinson’s, and even Type 2 diabetes. 

Funding: National Institutes of Health

Animation by Raul Perez

Read more »

As the Los Angeles fires quickly spread starting Jan. 7, with wind gusts approaching 100 mph, scientists observed a 110-fold rise in airborne lead levels. This spike had receded by Jan. 11.  

“This is a very well-deserved recognition for Srinivas as he joins the illustrious list of past recipients of the Charles Babbage Award,” said Vivek Sarkar, the John P. Imlay Jr. Dean of the College of Computing.

“Srinivas’ accomplishments reflect positively on himself and all of us at Georgia Tech. This is indeed an occasion to celebrate.”

The IEEE Computer Society presents the Babbage Award annually. The award recognizes significant contributions to parallel computation. 

[Related: IEEE-CS interview with Aluru on his award-winning career]

The award is named after Charles Babbage, widely considered to be a “father of the computer.” Babbage and Ada Lovelace are credited with inventing the first mechanical computers in the 19th century, eventually leading to more complex designs.

Aluru is a pioneer in computational genomics, an area of biology that studies the order, structure, function, and evolution of genetic material. Throughout his career, his lab has developed software and algorithms to analyze the genomes of several species of plants, animals, and microorganisms.

Genome base pair sizes can number into the billions, which can be interpreted as massive datasets. Ever since the early years of his career, Aluru championed parallel computing as a practical approach to studying these challenging datasets. 

Parallelism divides a large problem into smaller ones, allowing different processors on a computer to solve the simpler tasks simultaneously. This approach breaks a genome into smaller segments, allowing computers to efficiently transcribe genetic code and identify insightful patterns. 

“Srinivas Aluru’s groundbreaking contributions have profoundly shaped the intersection of parallel processing and bioinformatics. His work is nothing short of extraordinary,” said Yves Robert, awards chair of the IEEE Computer Society Babbage Committee. 

“It is a privilege to recognize a researcher whose work will undoubtedly have a lasting impact for generations to come.”

IEEE selected Aluru as a fellow in 2010, and he recently served as the editor-in-chief of the journal IEEE/ACM Transactions on Computational Biology and Bioinformatics. 

Aluru has fellowships with the American Association for the Advancement of Science, the Association for Computing Machinery (ACM), and the Society of Industrial and Applied Mathematics. He is a past recipient of the NSF CAREER Award, IBM Faculty Award, and the Swarnajayanti Fellowship from the government of India.

Along with receiving the Babbage Award, Aluru’s leadership acumen earned him the recent appointment as senior associate dean of Georgia Tech’s College of Computing. 

Aluru helped form the Institute for Data Engineering and Science (IDEaS) at Georgia Tech in 2016, serving as co-executive director. Later, he became the institute’s sole executive director from 2019 to 2025. Regents’ Professor C. David Sherrill became interim executive director of IDEaS when Aluru accepted his associate dean appointment.  

Aluru started at Georgia Tech in 2013 to join the new School of Computational Science and Engineering, established in 2010. He served as the School’s interim chair from 2019 to 2020. In 2023, the University System of Georgia appointed Aluru as Regents’ Professor.

Aluru completed his Ph.D. at Iowa State University in 1994. He then worked at Ames National Laboratory, Syracuse University, and New Mexico State University before returning to his alma mater from 1999 to 2013.

“This award is a recognition of over two and a half decades of research efforts in my group, reflecting not only my work but that of numerous graduate students and collaborators,” said Aluru. 

“I hope the award draws attention to the importance of parallel methods in computational biology and points key advancements to new entrants in the field.”

The team is developing innovative technology aimed at improving outcomes for patients undergoing cancer surgery. The project, entitled “MarginCall,” is set to transform how surgical margins are evaluated during cancer surgeries, with an initial focus on breast and ovarian cancer.

This innovative system enables real-time, precise evaluation of surgical margins, potentially reducing the need for repeat surgeries and enhancing patient care. Read the full story here.

“I am deeply honored by this recognition,” shared García. “I am thankful to all of those that made this award possible, notably my exceptional past and current trainees and collaborators as well as sponsors and funders. A big shout out to IBB and Georgia Tech – the supportive and collaborative multi-disciplinary ecosystem is truly unique and I am very proud to be part of this fantastic team.”

García was nominated for the award by IBB faculty member Ankur Singh. Singh is Carl Ring Family Professor in the George W. Woodruff School of Mechanical Engineering and the Wallace H. Coulter Department of Biomedical Engineering (BME) and directs the Center for Immunoengineering. “Andrés is an extraordinary, internationally acknowledged scholar who has also made exceptional contributions to the intellectual advancement of the field of bioengineering as a whole,” said Singh. “His work has revolutionized the design and application of biomaterial platforms, focusing on eliciting targeted tissue repair and developing innovative technologies that exploit cell-adhesive interactions. His work has generated deep mechanistic insights into the complex interplay between cell biology and mechanics, which have led to impactful translational applications that have significantly advanced healthcare solutions.”

García will be honored and present his recent work at an Award Ceremony during TERMIS EU 2025, which will take place from May 20-23 in Freiburg, Germany. 

Full press release here. 

The interdisciplinary degree is a joint effort across the Colleges of Sciences, Computing, and Engineering. The program expects to enroll its first graduate students in Fall 2025, pending approval by the Southern Association of Colleges and Schools Commission on Colleges.

The Institute Curriculum Committee has also approved a new Minor in Neuroscience, set to become available in the Georgia Tech 2024-2025 Catalog.

B.S. in Neuroscience

The Ph.D. and Minor offerings build on the recently launched Neuro Next Initiative in Research, and the established Undergraduate Program in Neuroscience, respectively.

Approved by the Board of Regents in 2017, the interdisciplinary B.S. in Neuroscience degree in the College of Sciences enrolled more than 400 undergraduate students in 2022, and has been  the fastest growing undergraduate major at Georgia Tech.

The B.S. in Neuroscience is also key to a strong ecosystem of undergraduate neuroscience education across the state, which includes peer programs at Mercer University, Augusta University, Georgia State University, Agnes Scott College, and Emory University.

Ph.D. in Neuroscience and Neurotechnology

The new doctoral degree will provide a path for the rapidly growing pipeline of in-state neuroscience undergraduate students and young alumni — while also welcoming a wider slate of graduate researchers to campus.

The Ph.D. Program’s mission is focused on educating students to advance the field of neuroscience through an interdisciplinary approach, with scientists and engineers of different backgrounds — ultimately integrating neuroscience research and technological development to study all levels of nervous system function.

Biological Sciences Professor Lewis A. Wheaton, who chaired the Ph.D. Program Planning Committee, shares that a cohort model will fuse “experimental and quantitative skill development, creating opportunities for students to work in science and engineering labs to promote collaborations, while also fostering a program and community that’s unique to the state and against national peer offerings.”

Expanding innovation — and impact

Wheaton explains that the new Ph.D. aims to equip graduates for a wide range of employment opportunities and growing specializations, including computational neuroscience, neurorehabilitation, cultural and social neuroscience, neuroimaging, cognitive and behavioral neuroscience, developmental neuroscience, and neurolinguistics.

The new degree will also help meet the country’s growing demand for a neuro-centric workforce. According to the U.S. Bureau of Labor Statistics, job growth for medical scientists (including neuroscientists) tracked around 13% between 2012 and 2022, faster than the average for all tracked occupations.

Wheaton adds that the program will equip neuroscientists to conduct research that can significantly improve lives.

Seeking students

The Planning Committee anticipates a tentative February 1, 2025 application deadline for Fall 2025 enrollments — and encourages students with the following interests to learn more and apply in the coming school year:

• Developing deeper quantitative, computing and/or engineering skills to make scientific discoveries that support innovations in neuroscience
• A clear, comprehensive understanding of the nervous system at all scales from molecular to systems
• Understanding how to use and innovate new tools and approaches to investigate the nervous system at all levels
• Becoming uniquely qualified to translate knowledge across neuroscience and related disciplines to create new knowledge in their professional pursuits

Director search

The participating Colleges will soon conduct a search for a program director, engaging a tenured member of the Georgia Tech faculty to serve as the new program’s administrator. A graduate program committee composed of five faculty members and mentors across the Colleges of Sciences, Computing, and Engineering, will also be created.
 

During their April 2024 meeting, Regents also announced budget approvals and tuition changes for Georgia's 26 member institutions.

The Ph.D. Program Planning Committee included the following faculty:

• Lewis Wheaton (Committee Chair, Biological Sciences)
• Constantine Dovrolis (Computer Science)
• Christopher Rozell (Electrical and Computer Engineering)
• Eric Schumacher (Psychology)
• Garrett Stanley (Biomedical Engineering)
• David Collard (College of Sciences Office of the Dean)

Farzaneh Najafi, an assistant professor in Georgia Tech’s School of Biological Sciences(SBS) , recently received multiple awards that will enable her to dig deeper into the molecular origins of cognitive processes, with the help of interdisciplinary teams.

“If we want to understand cognition, we really have to start small: at the level of molecules, genes, and the genome, and then work our way up to systems, behavior, and cognition,” says Najafi. “Impactful discoveries happen when people from different disciplines come together and collaborate. That’s how we make real breakthroughs.”

Two of her recent awards stem from the third and final year of the Scialog: Molecular Basis of Cognition initiative. Funded by the Research Corporation for Science Advancement (RCSA), the Frederick Gardner Cottrell Foundation, and the Walder Foundation, this initiative has provided 48 multidisciplinary teams with more than $2.4 million to advance this area of research.